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Summary 
 
Background: 
Diabetic kidney disease (DKD) is one of the most common and potentially most serious 
complications of Type 2 Diabetes affecting up to 40% of patients. Recent clinical studies 
suggest a beneficial role for bariatric/metabolic surgery in the treatment of DKD, the 
most notably Roux-en-Y gastric bypass (RYGB) procedure. The role of surgery, as an 
adjunct to medical therapy or as a stand-alone treatment that enables anti-diabetic 
medication to be withdrawn, is a source of current debate in this context. In the present 
study we used the Zucker Diabetic Sprague Dawley (ZDSD) rat, as a pre-clinical model of 
DKD to compare the trajectory, of urinary biomarkers of renal injury in the ZDSD rat, 
before and at 4 week follow-up in different intervention groups; 1) Sham surgery 2) 
Sham surgery plus 15% body weight loss and intensive medical therapy (Best Medical 
Treatment (BMT) 3) RYGB surgery and 4) RYGB surgery plus intensive medical therapy 
(RYGB-BMT). 
Method: 
Weight and glycaemia matched ZDSD rats were assigned to either the Sham (n=9), BMT 
(n=7), RYGB (n=9) or RYGB-BMT (n=9) groups when 25 weeks old. The medical regimen 
included metformin (300 mg/kg), rosuvastatin (10 mg/kg), fenofibrate (100 mg/kg) and 
ramipril (1 mg/kg) for all medically managed rats and titrated Liraglutide only for the 
weight loss group. Dietary weight loss of 15% was achieved through food restriction. 
Weight and blood glucose was measured weekly. Before and 4 weeks post intervention 
initiation, rats were placed in metabolic cages for urine collection. After 17 hours urine 
samples were collected and analyzed by multiplex ELISA for albumin, neutrophil 
gelatinase-associated lipocalin (NGAL), osteopontin (OPN) and kidney injury molecule 1 
(KIM-1). Age and sex-match Sprague Dawley rats served as healthy controls in the study. 
Results: 
Urinary excretion of albumin (r = 0.47), NGAL (r = 0.71), OPN (r = 0.64) and KIM-1 (r = 
0.55) correlates with the degree of hyperglycaemia (p < 0.01, Pearson’s test). Urinary 
albumin excretion is reduced in rats following BMT and RYGB (BMT) (p < 0.05, Wilcoxon 
test). In parallel, NGAL excretion into the urine increased in both BMT and BMT-RYGB 
groups (p< 0.05, Wilcoxon test). An elevation of the OPN excretion rate could be 
observed in the BMT and RYGB group (p< 0.05, Wilcoxon test), while none of the 
interventions had an influence on KIM-1 excretion rate. 
Conclusion: 
Intensive weight loss (dietary or arising post-surgery) in combination with intensive 
medical therapy effectively reduces hyperglycaemia and urinary albumin excretion in 
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ZDSD rats. The outcomes are better than in animals only undergoing RYGB surgery and 
without medical treatment. However, persistent elevation of urinary NGAL is suggestive 
of ongoing of tubular injury, potentially attributable to an aspect of medical treatment, 
rate of weight loss or a combination of both. 
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Zusammenfassung 
 
Hintergrund  
Die diabetische Nephropathie (DKD) ist eine der häufigsten und wahrscheinlich die 
gefährlichste Komplikation von Diabetes Typ 2. Über 40 % der Patienten können 
betroffen sein. Neuere Studien zeigen einen positive Effekt von 
bariatrischen/metabolischen Operationen als Therapie von DKD, besonders die Roux-en 
Magenbypass Operation (RYGB). Die Rolle der Operation in Kombination mit 
Medikamenten oder als eigenständige Therapieform, die das Absetzen der anti-
diabetischen Therapie ermöglicht, wird zurzeit heftig diskutiert. In dieser Studie 
benutzen wir Zucker Diabetic Sprague Dawley (ZDSD) Ratten als präklinisches Model 
für DKD. Die Tiere wurden in folgende Gruppen eingeteilt1) Sham Operation 2) Sham 
Operation plus 15% Körpergewichtsverlust und medikamentöse Therapie (Best Medical 
Treatment (BMT) 3) RYGB Operation und 4) RYGB Operation plus medikamentöse 
Therapie (RYGB-BMT). Anschliessend wurden diverse Biomarker für Nierenschaden 
bevor und vier Wochen nach der Intervention gemessen. 
Methode: 
Die ZDSD Ratten wurden nach Gewicht und Glykämie normalisiert und dann entweder 
der Sham (n=9), BMT (n=7), RYGB (n=9) oder RYGB(BMT) (n=9) Gruppe zugeordnet, als 
sie 25 Wochen alt waren. Das Medikamentenregieme bestand aus Metformin (300 
mg/kg), Rosuvastatin (10 mg/kg), Fenofibrate (100 mg/kg) und Ramipril (1 mg/kg) für 
alle Tiere in den medikamentösen Gruppen und zusätzlich Liraglutide nur für die BMT’s. 
Ein 15 %-iger Gewichtsverlust wurde durch Futterreduktion herbeigeführt. Das Gewicht 
und der Blutzucker wurden wöchentlich gemessen. Bevor und 4 Wochen nach dem 
Beginn der Interventionen, wurden die Ratten für 17 Stunden in metabolischen Käfigen 
gehalten. Anschliessend wurde der Urin eingesammelt und via multiplex ELISA auf 
Albumin, Neutropile gelatinase-associated lipocalin (NGAL), Osteopontin (OPN) und 
Kidney injury molecule 1 (KIM-1) untersucht. Sprague Dawley Ratten desselben 
Geschlechts und Alter galten als Kontrollgruppe. 
Resultat: 
Die Urinausscheidung von Albumin (r = 0.47), NGAL (r = 0.71), OPN (r = 0.64) und KIM-1 
(r = 0.55) korrelierte mit der Hyperglykämie (p < 0.01, Pearson’s Test). Die 
Albuminausscheidung war reduziert nach BMT und RYGB (BMT) (p < 0.05, Wilcoxon 
Test). Parallel dazu, erhöhte sich die NGAL-Ausscheidung in beiden Gruppen (p< 0.05, 
Wilcoxon Test). Erhöhte OPN-Ausscheidung konnte in der BMT und RYGB Gruppe 
beobachtet werden (p< 0.05, Wilcoxon Test). Keine der Interventionen hatte einen 
Einfluss auf die KIM-1 Ausscheidung.  
Konklusion 
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Intensiver Gewichtsverlust (diätetisch oder nach einer Operation) in Kombination mit 
intensiver medikamentöser Therapie reduziert die Hyperglykämie und 
Albuminausscheidung in ZDSD Ratten beträchtlich. Die Resultate waren besser, als in 
den Tieren, die nur eine RYGB Operation ohne medikamentöse Therapie hatten. Doch 
die erhöhten NGAL Werte deuten auf einen fortlaufenden tubulären Schaden hin. 
Möglicherweise verursacht durch die medikamentöse Therapie oder massiven 
Gewichtsverlust, oder einer Kombination von beidem. 
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1  Introduction 
1.1 Diabetic kidney disease in humans 
1.1.1 Epidemiology of diabetic kidney disease 
Worldwide over 420 million people have diabetes. The prevalence was 5.6% in 
Switzerland in 2016(1). About 30 % of them will develop diabetic kidney disease (DKD) 
and a small amount will progress to end stage renal disease (ESRD) (2) 
1.1.2 Symptoms of diabetic kidney disease 
The typical patient with DKD has a long history of diabetes, retinopathy and 
albuminuria, but without hematuria (3). Retinopathy can be absent in type 2 diabetes 
mellitus (T2DM) patients. DKD can be already present at diagnosis of T2DM. In type 1 
diabetes mellitus (T1DM) patients, DKD usually evolves 10 years after the diagnosis (4). 
Albuminuria can also be absent in DKD patients. Recent reports have shown the absence 
of albuminuria in some patients with reduced glomerular filtration rate (GFR)(5, 6). 
Sixty to 70% of the T2DM patients, who do not have proteinuria, have hypertension. 
Hypertension can cause development or progression of DKD. When the kidney is 
damaged, different factors, like the activation of the renin-angiotensin-aldosterone-
system (RAAS), can increase hypertension, thus creating a vicious circle. Mortality in 
patients with DKD is more often attributable to fatal cardiovascular events which occur 
prior to transition to DKD. 
1.1.3 Diagnosing diabetic kidney disease 
Kidney damage is associated with albuminuria, elevated plasma creatinine and reduced 
GFR. 
Albuminuria is mainly diagnosed in two ways, either by the albumin/creatinine ratio in 
the urine (UACR) in a random spot collection or via albumin measurement in a 24 hour 
urine sample collection (7). The 24 h urine albumin concentration test is the gold 
standard. However, the UACR is more convenient, because it can be performed during a 
general consultation. A UACR < 30 mg/g creatinine is considered normal, while n UACR 
????? ?????????????????????????????????????????????????? % and the specificity 60 % when 
??????????- 299 mg/g and 75 % respectively 99 ?? ??????????????? ????(8). Because 
the urinary albumin concentration is influenced by hydration, albumin should not be 
measured on its own (3). Fever, exercise, menstruation, hypertension and other factors 
can elevate UACR independent from kidney damage. The American Diabetes Association 
(2018) suggests repeating the UACR measurement within three to six months before 
diagnosing someone with albuminuria. In order to stage kidney disease, the estimated 
GFR (eGFR) should be calculated. At an early stage of CKD the eGFR increases due to the 
hyper filtration. Values of ? 120 ml/min/1.73 m2 can be measured. From stage 3 on the 
eGFR will drop to < 60 ml/min/1.73 m2 (9). More recently other kidney injury 
biomarkers have been proposed for use in prognostication in DKD and will be discussed 
in chapter 1.7. 
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1.1.4 Staging of chronic kidney disease 
In 2014 the Joint Committee on Diabetic Nephropathy made a new classification for 
diabetic kidney disease (10): 
Table 1 
Classification Urinary albumin [mg/g Cr] 
Urinary protein [g/g Cr] 
eGFR [ml/min/1.73 
m2] 
Stage I  
(prenephropathy) 
normoalbuminuria 
< 30 
? 90 
Stage II 
(incipient 
nephropathy) 
microalbuminuria 
30-299 
? 60-89 
Stage III 
(overt nephropathy) 
macroalbuminuria ? 300 
or proteinuria ? 0.5 
30-59 
Stage IV  
(kidney failure) 
albuminuria or proteinuria independent, no 
dialysis required 
<30 
Stage V  
(dialysis) 
albuminuria or proteinuria independent, 
dialysis required, 
< 30 
 
1.1.5 Risk factors 
Obesity and hypertension are important additional risk factors for developing CKD 
alongside diabetes (11). Treatment with antihypertensive medications such as 
angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers 
(ARB) is suggested, if blood pressure rises above 140/90 mmHg. The objective is to 
reduce the risk of cardiovascular events, such as myocardial infarctions and stroke (12, 
13). Patients with T2DM often show dyslipidaemia characterized by 
hypertriglyceridaemia, increased high-density lipoprotein (HDL) and decreased high-
density lipoprotein (HDL). Dyslipidaemia is associated with increased mortality and 
cardiovascular disease (CVD). Trough different pathomechanism high triglycerides and 
LDL can cause glomerular injury and increased matrix deposition into the 
tubulointerstitial space(14). 
1.2 Pathophysiology of DKD 
1.2.1 Histological findings DKD 
In humans` glomerular basement thickening, mesangial expansion and local to global 
glomerulosclerosis are common findings in DKD. The glomerular changes can be 
classified from I-IV. In addition tubular basement membrane thickening, 
tubulointerstitial fibrosis and tubular atrophy occur. Infiltration of the interstitium by 
immune cells can be present (15). The glomerular classifications and especially the 
amount of interstitial fibrosis and tubular atrophy have most likely an impact on 
progression to ESRD (16). Podocyte damage, loss and modification play an important 
role in developing albuminuria. Foot process effacement hypertrophy, detachment from 
the basement membrane and decreased density are already present in an early stage of 
DKD (17). Insulin is important for podocytes to react to increased intraglomerular 
pressure and increased GFR. Podocytes secret vascular endothelial growth factor A 
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(VEGF-A), which affects the endothelium cells. Too much VEGF-A (most likely present in 
DKD) and not enough VEGF-A (late state DKD) has negative effects on endothelium cells, 
thus weakening the glomerular filtration barrier further and worsening albuminuria 
(18) 
1.3 Pathophysiology DKD 
Diabetic kidney disease has multiple risk factors including hypertension, hyperglycemia 
and inflammation. These risk factors interact with each other and enhance the 
progression of DKD. 
1.3.1 Glucotoxicity 
Hyperglycemia induces the production of superoxide products which inhibit 
glyceraldehyde 3-phosphate dehydrogenase (GADPH), which transforms 
glyceraldehyde-3 phosphate with the help of nicotinamide adenine dinucleotide (NAD+) 
into 1,2 diphosphoglycerate. Glycolysis in the cell is reduced and more products 
upstream of 1,3 Diphosphoglycerate are available. This leads to activation of parallel 
substrate utilisation pathways. (19) The now increased glucose levels in the cell can lead 
to an augmented sorbitol and fructose production, by activating the polyol pathway. 
Increased fructose levels have been associated with proteinuria, and increased 
mesangial matrix expansion and tubular injury (20). In addition the production of 
sorbitol uses nicotinamide adenine dinucleotide phosphate (NADPH), leading to a 
decreased regeneration of glutathione, more reactive oxygen species (ROS) are formed 
(21). In summary increases production of sorbitol and fructose might lead, via ROS, to 
direct and indirect kidney damage. 
More fructose-6-phospate leads to increased glucosamine 6-phospate (glucosamine-6P) 
production, via the hexosamine pathway. Glucosamine-6-P influences the production of 
tumour necrosis factor alpha (TNF-?), promoting inflammation. In addition it increases 
tissue growth factor beta(TGF-?), which leads to renal cell hypertrophy and augmented 
mesangial matrix deposition, narrowing the lumen of the glomeruli.(19) Glucosamine-6-
P can be metabolized further and impair nitric oxide (NO) production, (22). High 
intracellular glucose levels enhance the production of advanced glycation products 
(AGE). They can impair and modify not only intracellular, but also extracellular proteins 
or increase the production (19). AGE’s are associated with more extracellular matrix 
(ECM) accumulation in the glomeruli. Changes in collagen IV and laminin by AGE’s have 
been demonstrated to increase the permeability of the glomerular basement membrane 
(GBM). AGE can bind to inflammatory receptors and enhance inflammation as well as 
increasing pro-fibrotic factors, like VEGF and connective tissue growth factor (CTGF), 
both associated with hypertension and proteinuria (19, 23, 24). In summary AGE’s 
induce ECM expansion, increase GBM permeability, proteinuria and fibrosis. 
Another important pathway is the protein kinase C pathway (PKC). PKC increases CTGF, 
TGF-?? collagen IV production enhancing further GBM thickening, glomerular and 
tubular hypertrophy and sclerosis(19). In addition PKC increases the activity of nitric 
oxide (NO), which dilates the afferent arteriole in the glomerulus. It also enhances the 
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vasoconstrictive effect of angiotensin II (Ang II) on the efferent arteriole, leading to 
glomerular hypertension and increased GFR (25). 
1.3.2 Glomerular hypertension 
Increased glucose levels in combination with hyperinsulinemia lead to augmented 
glucose reabsorption in the kidney. As a side effect sodium reabsorption in the proximal 
tubules is increased. As consequence the macula densa will sense low sodium levels and 
activate sodium retention mechanism, like the renin-angiotensin-aldosterone system 
RAAS). The volume expansion leads to dilatation of the afferent arteriole in the 
glomerulus. The intraglomerular pressure rises and the GFR increases. 
Early stage of DKD is now present with an increased GFR. In addition renin, aldosterone 
and especially angiotensin have further effects on the kidney. Angiotensin increases the 
intra glomerular pressure by contraction of the efferent arteriole and can damage 
podocytes directly. The full RAAS enhances over different pathways kidney 
inflammation, renal cell loss, extracellular matrix accumulation, oxidative stress, 
mesangial cell expansion and glomerular hypertrophy, leading finally to DKD and 
progressing the disease(26). 
Other factors are increased in patients with DKD. Endothelin 1 (ET-1), secreted by 
mesangial, glomerular and renal tubular cells, induces vasoconstriction, fibrosis, 
podocyte injury, mesangial cell proliferation and ECM production. It also activates 
receptors that can directly increase the glomerular permeability (27). Finally the 
amount of NO seems to decrease, reducing the vasodilatation of the afferent arteriole 
and more and more cells being damaged, leading to a reduced GFR and progression of 
DKD to ESRD (28). 
1.3.3 Inflammation 
Many inflammation factors, like TNF-??????????????-1 and interleukin-6 are increased in 
kidney of diabetic people. They can lead to apoptosis of endothelial cells, GBM 
thickening and increase of the permeability for proteins (19). Further inflammatory 
pathways have been found activated, like the Janus kinase/signal transducer and 
activator of transcription proteins (Jak/STAT) or the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-??). Both pathways induce glomerular changes, 
leading to hypertrophy of mesangial cells, increasing GFR, apoptosis of other renal cells 
and proteinuria (29, 30). 
In summary, there are many factors increasing ECM deposition, renal cell hypertrophy, 
apoptosis fibrosis, glomerular hypertension and inflammation. It leads first to an 
increased GFR and while the glomerulus becomes more and more crowded, the GFR 
decreases. The apoptosis of cells and change of the basal membrane leads to leakage of 
the glomeruli, becoming apparent by the proteinuria.   
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1.4 Therapy of diabetic kidney disease 
1.4.1 Management of diabetic kidney disease patients 
The American Diabetes Association (ADA) suggests starting DKD treatment before the 
patients show albuminuria. The goal is to prevent the development of albuminuria by 
controlling risk factors such as hyperglycemia, hypertension, dyslipidaemia and 
smoking (3). In addition the patient’s urinary albumin should be revaluated at least once 
a year.  
If microalbuminuria is present, it is the goal to prevent progression to 
macroalbuminuria. Hyperglycaemic, hypertensive, dyslipidaemic control have to be 
intensified. Good glycemic control can reduce the progression to ESRD (31). Dietary 
changes (reduced protein and salt intake) and moderate exercise should be considered. 
When the GFR is depressed, drug dosage adjustment should be made. Vaccination 
against Hepatitis B should be considered and bone density and vitamin D 
supplementation controlled. If the GFR further declines electrolytes, bicarbonate, 
calcium, phosphorus, parathyroid hormone, haemoglobin, albumin, and weight should 
be controlled every 3–6 months. When the GFR < 30 ml/min/1.73 m2 the patient should 
be referred to a nephrologist to discuss renal replacement therapy (32). 
1.4.2 Dietary suggestions 
1.4.2.1 Reduce protein 
Protein intake in non dialysis dependant patients should be reduced to maximal 0.8 g/kg 
per day. A daily intake of more than 20 % protein, increases albuminuria and enhances 
the progression of CKD. However, the protein amount may have to be increased in 
dialysis dependant patients, due to proteinuria (33). 
1.4.2.2 Reduce sodium and potassium 
Patients with DKD often have salt sensitive hypertension and hyperkalemia. The 
reduction of sodium and potassium can lower blood pressure, protect excitable tissue 
function and have a positive effect on the progression of CKD (34, 35). 
1.4.3 Glycemic control 
Good glycemic control has been shown to decrease progression of DKD to ESRD (31). At 
an early stage patients with T2DM can be treated with metformin, but it is 
contraindicated if GFR < 30 ml/min/1.73 m2 (33). If glycemic control cannot be achieved 
with only metformin, the American Diabetes Association (2018) suggests adding 
another drug, like GLP-1 receptor agonists or baseline insulin. The patient should be 
revaluated 3 months later. In case the glycemic target is still not reached, a triple drug 
therapy can be considered (36). 
1.4.4 Antihypertensive therapy: Angiotensin-converting-enzyme (ACE) inhibitors 
/Angiotensin II receptor blockers (ARB’s) 
Hypertension is a risk factor for CKD. Blood pressure control is suggested from 140/90 
mmHg on (12). Reduction of blood pressure decreases albuminuria significantly and 
reduces the risk of cardiovascular events (13). Both, ACE inhibitors and ARB slow down 
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the progression of CKD (37), but they should not be given in combination. Together they 
increase the risk of hyperkalemia and acute renal insufficiency (AKI) (38).   
Antihypertensive therapy should not be started as long as the patients do not suffer 
hypertension, because otherwise the risk of cardiovascular events is too high (39). 
1.4.5 Control of dyslipidaemia 
Dyslipidaemia is associated with increased mortality and more prevalent in patients 
with DKD(14). Rosuvastatin blocks the production of LDL and increases the HDL in the 
blood. It reduces tubular damage in patients with DKD (40).   
Fibrates are peroxisome proliferator-activated receptor (PPAR’s) analoga. They improve 
the insulin sensitivity and the glucose uptake into the striate muscles and the adipose 
tissue. In a diabetic mouse model, fenofibrate reduced albuminuria and glomerular 
injury (41, 42).  
1.4.6 Exercise/weight loss 
Weight loss, especially in prediabetic patients has been shown to reduce the risk to 
develop diabetes significantly (43). 
1.5 RYGB 
1.5.1 What is RYGB? 
Roux-en Y gastric bypass surgery (RYGB) can be used for weight loss and or as a 
treatment of type 2 diabetes. The stomach is divided into a smaller upper pouch (about 
15 ml volume) and a bigger lower pouch (about 400 ml). The jejunum is transsected 
proximally. The distal end of the jejunum is then attached to the smaller upper stomach 
pouch to form an anastomosis to bypass most of the stomach and the duodenum. The 
remaining jejunum stump, continuous with the larger stomach remnant and the 
duodenum is then anastomosed to the downstream jejunum to form the Y shape of the 
reconstruction (44). The anastomosis could also be done in the ileum, but there are 
more complications. Because more of the small intestine is bypassed, there is more 
malabsorption (mainly starch and fat), reduced vitamin and mineral uptake and more 
undigested food arrives in the colon where micro flora can use it to produce gas(45, 46). 
The complication rate of the surgery is 4% within the first 90 days but up to 20% over 
the lifetime of the patient. Complications after surgery are: Prolonged nausea and 
vomiting, haemorrhages, wound infection and peritonitis, anastomotic leakage or 
stricture (44, 47).  
1.5.2 Indications 
At the 2nd diabetes surgery summit (DSS-II) the new guidelines for metabolic treatment 
were presented. For all obese people with a BMI ? 40 kg/m2 and Asians ? 37.5 kg/m2, as 
well as T2DM patients with poor glycemic control and BMI ? 35 – 39.9 kg/m2 (Asians ? 
32.5 -37.5 kg/m2), bariatric surgery is recommended. For everyone with T2DM, good 
glycemic control and a BMI ? 35 – 39.9 kg/m2 (Asians ? 32.5 -37.5 kg/m2) or T2DM 
patients with bad glycemic control and a BMI ? 30 – 34.9 kg/m2 (Asians ? 27.5 -32.4 
kg/m2) metabolic surgery should be considered as an alternative to medical treatment. 
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Bariatric surgery should not be performed in non obese or T1DM patients (32). 
1.5.3 Advantages 
The most important effect is the weight loss. In a Swedish obese study patients lost 25% 
weight over 20 years (48). Hyperlipidemia can be reduces in most patients. 
Hypertension is decreased in almost all patients. Type 2 diabetes improves in many of 
the patients, and the risk to develop T2DM can be reduced 30x in patients undergoing 
surgery in a prediabetic state (49). Bariatric surgery reduced the progression from early 
stage CKD to ESRD (50). In other studies the plasma OPN levels were monitored before 
and after bariatric surgery. Plasma OPN levels were high prior to surgery and did not 
decrease after surgery. This was possibly because of the increased bone markers, caused 
by the adaption of the bones to the weight loss (51, 52).  
1.5.4 Risk factors 
The disadvantages of bariatric surgery are the reduced uptake of vitamins, especially 
Vitamin B12 and fat soluble vitamins. These vitamins have to be taken as supplements 
(53, 54). The iron and calcium uptake is reduced, because the duodenum is bypassed, 
where most of it is absorbed. The low iron levels can lead to pica(55). There are reports 
of people suffering depression after surgery, because of the change of what can be eaten 
and the amount of it (56). Muscular weakness can occur, because of a reduced protein 
intake. It can lead to balance problem and increased fatigue end early exhaustion 
(54).Further complications of RYGB surgery are: Increased risk of gallstone formation 
and kidney stone formation (57, 58) 
Bariatric surgery slightly increases the bone fracture risk, especially in combination with 
malabsorbtion (59, 60). Different mechanisms are proposed to be the cause. 
Malabsorbtion of Vitamin D leading to secondary hyperparathyroidism and reduced 
skeletal loading, because of weight loss, are associated with decreased bone density. 
Bone turnover markers are elevated (61, 62). In a previous study, Riedl et al. (2008) 
found that plasma OPN did not decrease after bariatric surgery. He explains it with the 
increased bone turn over, since OPN is involved in bone remodelling (63). 
1.6 Rodent models for diabetes 
There are many different rodent models for diabetes. In general, diabetes can be induced 
via injection of a chemical agent, such as Streptozotocin (STZ), provoked via diet, genetic 
defects or viral infections (64). 
1.6.1 Type 1 diabetes mellitus models 
Streptozotocin (STZ) can be used to induce diabetes in rats and mice (65). It destroys 
the ?-cells in the pancreas. This model is often used for studying T1DM. It is cheap, but 
STZ can be toxic to other organs (66). Multiple injections of lower dose STZ leads to 
diabetes and it has less negative effects on other organs (65). 
The non obese diabetic (NOD) mice develop diabetes at 12 – 14 weeks of age in females. 
T1DM is caused, due to severe pancreatic islet inflammation. In addition to diabetes, 
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NOD mice also are likely to develop other autoimmune diseases (67). There are other 
rodent models that will develop T1DM spontaneously, like the BB rat. 
AKITA mouse has a mutation of the Ins2 gene resulting in abnormal folding of Insulin, 
which then loses functionality. These animals only exhibit modest kidney changes and 
are not an ideal model of T2DM. (68) 
There is the possibility to induce diabetes via viruses, but this is more appropriate to 
understand the involvement of viruses in the pathogenesis of T1DM (64). 
1.6.2 Type 2 Diabetes rodent models 
1.6.2.1 Mice 
1.6.2.1.1 Leptin receptor deficient mice 
Leptin-deficient ob/ob and db/db mice have a defect in the leptin receptor. This leads to 
hyperphagia, obesity, hyperinsulinemia, hyperlipidemia and finally to insulin resistance. 
Kidney changes can be observed, like reduced GFR, ECM expansion and podocyte loss. 
Tubulointerstitial fibrosis and nodular sclerosis does not occur and therefore does not 
exactly mimic the changes observed in humans. Leptin deficiency is also a very rare 
cause for T2DM in humans (69). 
1.6.2.1.2 Diet induced diabetes 
Mice, usually from the C57BL/6 strain, can be fed a high fat diet to develop obesity, 
insulin resistance, dyslipidaemia and hyperglycaemia. Environmental conditions and 
gender also play important roles (70). 
1.6.2.2 Rats 
1.6.2.2.1 Zucker Diabetes Sprague Dawley (ZDSD) rat 
The ZDSD rat is bread from a lean Zucker Diabetic Fatty (ZDF) male rat and a female 
member of the Crl:CD(SD) rat and then selectively bred for obesity. They have an intact 
leptin pathway. Male ZDSD develop spontaneously T2DM with normal chow (71). ZDSD 
have a long prediabetic state, starting already at seven weeks of age. They show signs of 
metabolic syndrome with hyperglycemia, hyperinsulinemia, decreasing glucose 
tolerance and increasing insulin resistance and hyperlipidemia. The long prediabetic 
period mimics what happens to humans who develop T2DM. They start developing 
overt diabetes, when 19 weeks of age. Insulin decreases, because of ?- cell failure. They 
exhibit polyuria and polydipsia and glucose intolerance (71). When they are 24 weeks 
old they are likely to develop complications as diabetic kidney disease with progressive 
albuminuria and decreased GFR. Urinary kidney injury markers such as kidney injury 
molecule 1 (KIM-1), ?-microglobulin, clusterin and cystatin are elevated. ZDSD rats also 
develop glomerular basement membrane (GBM) thickening and mesangial matrix 
expansion, making it to a better model for DKD than most other rodents. However, ZDSD 
are a rather new model and a lot of information about the pathogenesis of DKD in this 
rats is still missing (72). 
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1.6.2.2.2 Zucker Diabetic Fatty (ZDF) rat and other leptin receptor deficient rats 
The ZDF rats have a defect in the leptin receptor and also a defect in the ?-cell 
transcription (73). It is one of the most used rodent models for T2DM. Male homozygous 
fa/fa ZDF develop obesity spontaneously, because of hyperphagia. When 8 weeks old the 
?-cells start failing, and T2DM develops fast, without a long prediabetic state. Kidney 
changes are moderate, only at a late stage (at 22 weeks) they develop focal and 
segmental tubulosclerosis and moderate mesangial expansion (74). In addition they can 
develop hydronephrosis, which does not make them ideal to study DKD. In addition 
leptin receptor defect is a rare cause for T2DM in humans (69). 
 
The ZSF-1 rat were bred from ZDF and a spontaneously hypertensive heart failure 
(SHHF) rat. Like the ZDF they have a mutation in the leptin receptor. They become 
obese, due to hyperphagia and the males will develop T2DM with hyperglycemia and 
proteinuria. Their kidney changes are more similar to the human DKD form. They show 
tubulointerstitial fibrosis, mesangial expansion and (GBM) thickening and tubules 
dilatation and atrophy (75, 76). They also show a severe hyperlipidemia, which is not 
present in this form in humans with T2DM (76). 
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1.7 Urinary kidney injury markers 
The following urinary kidney injury markers were used in this study to assess kidney 
injury in the used rodent models: neutrophile-gelatinase-associated lipocalin (NGAL), 
Osteopontin (OPN), kidney injury molecule 1 (KIM-1) 
1.7.1 Neutrophil gelatinase- assosciated lipocalin (NGAL) 
1.7.1.1 Pathophysiology of NGAL 
NGAL is also known as lipocalin 2. It is from the lipocalin superfamily. The protein 
consists of eig?????????????????-?????????????????????????????????????(77). It is expressed 
and secreted by different cell in the body including hepatocytes and renal tubular cells, 
when pathology present. NGAL has a bacteriostatic effect by capturing and depleting 
siderophores, thus reducing the free iron (77). It is involved in the growth and 
differentiation of mature renal epithelium and its organisation in the tubules. 
1.7.1.2 NGAL obesity 
NGAL expression is up regulated in adipose tissue of obese mice and humans (78). De 
Muro et al (2016) showed that urinary NGAL (uNGAL) can be elevated before the onset 
of microalbuminuria. He highlights that uNGAL is increased when tubulus damage 
occurs, which one of the early changes in the diabetic kidney(79). 
1.7.1.3 NGAL and the kidney 
NGAL is a good marker for tubulo-interstitial damage. In case of kidney damage it is 
mainly up regulated in the ascending loop of Henle, the distal tubules and the collecting 
duct (77). NGAL is up regulated after ischaemic or nephrotoxic acute kidney injury, but 
it can be also up regulated in chronic kidney disease and is an important factor for 
progression, even independent from the GFR. Its expression in the kidney correlates 
with the severity of the lesions (80, 81). In a study with 77 patients with T2DM high a 
level of urinary NGAL excretion was associated with a faster decline of the GFR and 
progression of DKD (82)  
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1.7.2 Osteopontin 
1.7.2.1 Pathophysiology of osteopontin 
Osteopontin (OPN) was first discovered in 1985 (83) and is also known as secreted 
phosphoprotein 1 (SPP) or early T-lymphocyte activation (ETA-1). It is a small integrin-
binding ligand, N-linked glycoprotein (SIBLING) protein (84). OPN is encoded by the SPP 
1 gene, it has 7 exons, is 5kb long and can be found on chromosome 4 in humans (85). 
The SPP 1 gene in mice is located on chromosome 5 (86) and in the Rattus norvegicus on 
chromosome 14. The size of OPN differs from 41 – 75 kDA, because of post-translational 
modifications (87). OPN can be found in all body fluid, such as milk, urine, blood liquor. 
It is secreted in many locations, including cartilage, teeth, kidney: especially podocytes 
and in the distal renal tubules, brain, vascular tissues, mammary, activated macrophages 
and lymphocytes (88). OPN is secreted as full length OPN, OPN-b lacks exon 5 and OPN-c 
lacks exon 4 (89). There are signs that different forms of OPN might be present at 
different stages of diseases. Kiefer (2008) found that OPN-a was reduced in the adipose 
tissue of obese people, while OPN – b was elevated and OPN – c unaltered. 
OPN exists in different forms. The secreted form (sOPN) works as a cytokine and its 
intracellular form (iOPN), found in the cytoplasm, is responsible for the arrangement of 
the cytoskeleton. Both forms are generated from the same DNA sequence, but are then 
differentiated through different translational initiation sites (90). sOPN is involved in 
the immune response regulation, by decreasing IL-12 and increasing IL 10 (91). It can 
inhibit apoptosis via integrins (92) and OPN seems to play an important role in tumour 
progression and metastasis (93, 94). OPN affects most cells via ????????????-Integrins, 
that are mainly binding to the Arg-Gly-Asp (RGD)- binding site of OPN (87). It can also 
bind to CD44 (Asou 2001). 
OPN plays a role in bone remodelling and bone formation and it stimulates the adhesion, 
migration and bone resorption by osteoclasts (95). Elevated levels of OPN have been 
found in autoimmune diseases such as multiple sclerosis or lupus erythematosus (96, 
97). OPN is elevated and involved in the mineralization of soft tissue for example 
vascular calcification and valvular calcification (98, 99). It also plays a role in the 
formation of renal crystals (100). OPN can modulate the inflammatory response by 
modulating the migration and cytokine release of white blood cells (101). 
1.7.2.2 OPN in obesity and diabetes 
Elevated OPN has been found in the adipose tissue of obese patients. Macrophages are 
thought to be the main source of the OPN; during adipose tissue inflammation, 
interestingly plasma OPN was just slightly increased (102). In OPN -/- obese mice, the 
amount of macrophages in the adipose tissue was decreased, suggesting that OPN plays 
also a role in the attraction of macrophages (103). Dietary weight loss and exercise 
reduces the OPN level (104). Kahles (2014) suggests that OPN plays a key role in the 
development of insulin resistance when rats are fed with high fat diet. The reason is the 
impairment of the differentiation and insulin sensitivity of adipocytes, mediated by OPN 
through different receptors (105).  
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1.7.2.3 OPN and CKD 
OPN is expressed by the distal tubular epithelial cells. In the case of kidney damage, it 
can also be up-regulated in the glomeruli and by the macrophages found in the 
parenchyma (106, 107). Increased plasma OPN was associated independently of the 
severity of the nephropathy and albuminuria in patients with T2DM (108). OPN -/- mice 
did not have albuminuria and were protected from renal damage (109). OPN is 
responsible for the stress adaption in podocytes, caused by hypertension (Schordan 
2010). The administration of ACE inhibitors reduces the OPN level (106). 
1.7.3 Kidney Injury molecule 1 (KIM-1) 
1.7.3.1 Pathophysiology of Kim-1 
Kidney injury molecule 1 (KIM-1) is also known as T-cell immunoglobulin domain and 
mucin domain 1 (TIM-1) or hepatitis A virus cellular receptor 1 (HAVcr-1). It is a type 1 
membrane glycoprotein with 6 cysteine immunoglobulin-like domains and a mucin 
domain and N- and O-glycosylation sites. In the kidney, it is involved in the apoptotic cell 
phagocytosis and acts as a receptor to transform the proximal tubulus epithelium cells 
into semi-professional phagocytes enhancing their uptake of necrotic cell debris (110).  
1.7.3.2 KIM-1 and chronic kidney disease 
KIM-1 is not detected in healthy kidneys, but it is highly up regulated in the proximal 
tubules epithelium in case of acute or chronic kidney injury. A huge amount of it is 
secreted into the urine, making it a good biomarker for kidney damage (111). 
1.7.3.3 KIM 1 and diabetes 
Increased KIM-1 levels in the urine have been described in patients with type 1 and type 
2 diabetes mellitus. Vaidya et al. (2011) reported that a regression of albuminuria led to 
a decrease of KIM-1 in patients with T1DM (112). Patients with an increased KIM-1 
without proteinuria progress earlier to more severe kidney diseases stages (113). 
Nielson et al. (2012) described a faster decline of the GFR in T2DM patients with 
elevated KIM-1 in the urine (82) 
KIM-1 is elevated in obese patients with normal kidney function. Six months after RYGB 
surgery the urinary KIM-1 levels increased and decreased 1 year post surgery. (114) 
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1.8 Research Questions 
The overarching research question under investigation in this thesis was to explore the 
differential impact of types and degrees of weight loss with and without intensive 
medical therapy on excretion of urinary biomarker surrogates of kidney injury. I 
hypothesised that ZDSD rats after RYGB combined with best medical treatment would 
have lower urinary kidney injury marker levels. The aims of my study are: 
Aim 1 assessed the penetrance of the diabetic phenotype in ZDSD rats at the age of 26 
weeks and examined, whether this tracked with level of injury biomarkers in the urine  
Aim 2: quantified the relative impact of 3 intensive weight loss and metabolic control 
interventions on urinary kidney injury markers excretion in ZDSD rats. 
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2 Materials and Methods 
2.1 Study design 
The full study was approved by University College Dublin Animal Research Ethics 
Subcommittee (AREC) and work conducted under a governmental license from the 
Health Products Regulatory Agency-Ireland. 
 
Schema 1General study plan on the ZDSD rats 
The schema represents the timeline of the experiments and the subdivision of the ZDSD rats. 
Sham (positive control), BMT (best medical treatment), RYGB (Roux-en gastric bypass surgery). 
 
2.1.1 Animal husbandry 
All rats for the experiments were housed in the Biomedical Facility of the University 
College Dublin, Ireland. Forty four male Zucker Diabetic Sprague-Dawley rats (ZDSD) 
and seven Sprague-Dawley (SD) rats were obtained from CrownBio (Belgium), at the age 
of 14 weeks. The SD rats were used as the healthy control, because they are related to 
the ZDSD. All rats were housed (2/cage for the ZDSD and 3 – 4/ cage for the SD) in a 
controlled environment for humidity (35%), constant temperature (22 ± 1°C) and a 12 
h:12 h light/dark cycle (lights on at 7 am). They were fed standard chow (Purina 5008 
4.36 kcal/g, protein 23.6 %, fat 6.7 %) and water ad libitum.  
2.1.2 Pre-surgery handling and division into experimental groups 
From 16 weeks of age, all rats were weighed weekly. In addition from 23 weeks of age, 
plasma glucose was measured weekly.  
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At 25 weeks of age, 43 of the ZDSD rats were divided into 4 groups, equalized for their 
weight and plasma glucose and their KIM-1, Albumin, OPN and NGAL concentration in 
the urine. The numbers of rats in the two RYGB groups were higher, because of expected 
loss of animals during surgery. 
a. Sham group (7 rats) 
b. Medical treatment and 10 % weight loss (BMT) (8 rats) 
c. RYGB group (14 rats) 
d. RYGB group and medical treatment (RYGB(BMT)) (14 Rats) 
e. Control (7 SD rats) 
Post RYGB surgery, an adjustment of the animals per group was made, because some 
rats were lost after surgery. Two rats did not undergo surgery, but were added to the 
sham group. The final groups were: 
a. Sham group (9 rats) 
b. Medical treatment and 10 % weight loss (BMT) (7 rats) 
c. RYGB group (9 rats) 
d. RYGB group and medical treatment (RYGB(BMT)) (9 Rats) 
e. Control (7 SD rats) 
2.2 Interventions 
2.2.1 Surgery 
2.2.1.1 Sham surgery 
At 25 weeks of age, the rats in the sham and BMT group received a sham surgery 
(laparotomy only). For seven days prior to surgery all animals were treated with long-
acting insulin degludec (Tresiba®, Novo Nordisk A/S) according to their blood glucose. 
For dosage detail see appendix chapter 6.1. Rats were not fasted prior to surgery.   
The animals were anesthetized using Isoflurane. They were laid out supine and a 2 cm 
midline abdominal incision was made. The stomach and intestine were made visible. 
The abdomen was then closed in two layers: First the abdominal muscles with a 
continuous and the skin with interrupted stitches. Vicryl 4-0 (Ethicon, Inc.) was used for 
both layers. The rat was put into a clean cage with paper and a warming pad to recover 
from anaesthesia. When fully recovered the rat were returned to a clean home cage. 
2.2.1.2 RYGB surgery 
The RYGB surgery was performed when the rats were 29-30 weeks old. Animals were 
treated for 7 days prior to surgery with long-acting insulin degludec (Tresiba®, Novo 
Nordisk A/S) according to their blood glucose. For dosage detail see appendix chapter 
6.1. The day before surgery only a half dose was administrated. The animals were 
anesthetized using isoflurane. They were laid out supine and a midline abdominal 
incision was made. The proximal jejunum was divided 10 cm distal to the pylorus to 
create the biliopancratic limb and an alimentary limb. The biliopancratic limb was then 
sutured, via side to side jejuno-jejunoanastomosis, 30 cm proximal from the caecum to 
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the small intestine. The stomach was divided close to the gastro-oesophageal junction 
into a small pouch (max 3 ml volume) and a bigger pouch. The small pouch was stitched 
to the alimentary limb via end to side anastomosis. The remnant gastric pouch was 
closed using a continuous suture. Five ml of warmed, sterile saline (0.9%, 3.5 ml each 
side) were given intra peritoneal before closure. The abdomen was closed in two layers 
with continues stitches, using Vicryl 4-0 (Ethicon, Inc.) for the linea alba and another 
Vicryl 4-0(Ethicon, Inc.) for a modified intracutan stitch to close the skin. 
2.2.1.3 Post-surgical care 
Post surgery the animals were housed for 3 days without bedding, to prevent aspiration. 
They received five days of prophylactic treatment with enrofloxacin (7.5mg/kg) and one 
to three days buprenorphine (0.05mg/kg), as required. Only water was available ad 
libitum at the day of surgery. On day one and two post surgery the rats received 20ml 
respectively 30 ml of liquid diet (Ensure® Plus, Vanilla, 1.5kcal/ml, 16.7% protein, 
29.5% fat, 53.8% carbohydrate) to facilitate passage through the oedematous surgery 
part of the gastrointestinal tract and reduce damage. On day three they were returned 
onto normal bedding and were fed wet mash. On day seven post surgery all rats 
returned to normal chow (Purina 5008). Five rats received normal chow already on day 
6 post surgery, because they haven’t been eating the wet mash well. During the first ten 
days post surgery the ZDSD were monitored daily for weight loss, food and water intake, 
pain and sings of infection. If the weight loss was > 30% the animal was euthanized. For 
more details regarding pain scoring see appendix 6.3.  
Some rats showed hypersalivation, porphyria and reduced food intake >14 d post 
surgery. The normal chow was substituted for two days by a rat smoothie (Purina 5008 
crushed, and soaked in water, 5 ml of Ensure® Plus and water to adjust the viscosity). 
2.2.2 Food restriction and medical treatment of BMT group 
The food of the BMT rat was reduced, when 29 weeks old. The goal was 10% weight loss 
in three weeks. Initially all received 16 g of standard chow (Purina 5008). The weight 
was controlled every 3 days and the amount of food given, was adjusted +2 g, 0 or –2 g, 
according to their weight change. In addition they received metformin hydrochloride 
(300mg/kg). After 10 days blood glucose was measured. All BMT rats received then in 
addition to metformin also rosuvastatin (10mg/kg), fenofibrate (100mg/kg) and 
ramipril (1mg/kg). When the 10% weight loss was achieved liraglutide treatment was 
started. The dose was titrated over 14 days to 1mg/kg subcutaneous. In this period 
water intake was monitored to avoid dehydration. At day 11 the Liraglutide treatment 
was interrupted due to massive weight loss. All BMT rats received then 30g of chow/day 
to regain weight towards target. Liraglutide was reinitiated at 0.2mg/kg.  
metformin, rosuvastatin, fenofibrate and ramipril were given orally. The tablets were 
ground to a powder using a mortar and pestle, dissolved in water and then distributed 
over the rats daily chow ration. 
2.2.3 Best medical treatment of RYGB(BMT) group 
After RYGB surgery, the rats were given few days to recover. When all rats from the 
RYGB(BMT) group were at least 7 day post surgery, they received metformin 
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hydrochloride (300mg/kg) with 20g standard chow. Two days later rosuvastatin (10 
mg/kg), fenofibrate (100mg/kg) and ramipril (1mg/kg) were added. Three weeks post 
surgery the chow ration was increased to 25 g/day, to ensure ad libitum food intake. 
Metformin, rosuvastatin, fenofibrate and ramipril were given orally. The tablets were 
grounded to a powder using a mortar and pestle, dissolved in water and then distributed 
over their daily chow ration. 
2.3 Procedures 
2.3.1 Blood glucose 
Plasma glucose was measured using Contour® Glucose strips (Bayer Ltd, Dublin 
Ireland). Blood was obtained by puncturing the lateral tail vein and measured using the 
Bayer Contour Blood Glucose Meter. The maximum detection limit for glucose was 33.3 
mmol/L. Values above that could not be measured and were thus included in statistical 
analyses as 33.3 mmol/L.  
2.3.2 Blood plasma 
Blood plasma was obtained by puncturing the lateral tail vein at the most distal point. 
The blood was collected by allowing it to drop into a 300 μl heparin coated tube. The 
blood was centrifuged for 5 min with 2000 rpm. The plasma was pipetted into an 
Eppendorf tube and then stored at -20° C till analyzed. 
2.3.3 Metabolic cages 
The ZDSD and SD rats were put into metabolic cages to collect urine when 23 and 26 
weeks old. In addition urine was collected four weeks after initiating the intervention of 
each study group (when 33 – 34 weeks old). The rats spent 15 -18 h in the metabolic 
cage. The urine was used to measure albumin, NGAL, OPN, KIM-1 and creatinine, to 
assess kidney damage. In addition food intake, urine production and water intake were 
measured when 26 weeks old.    
The collected urine was centrifuged for five min with 2000 rpm and then pipette into 
Eppendorf tubes for storages in the freezer at -20° C. 
2.3.4 24 hour food intake 
The food intake was measured at 7:00, 13:00, 19:00 and again at 7:00 of the following 
day. The measurement was performed when all rats were 34 weeks old. 
2.4 Definition of diabetes 
An afternoon plasma glucose of < 7 mmol/L was considered normal, 7.7 mmol/L – 11.0 
mmol prediabetic and >11.0 diabetic. Plasma glucose of > 7 mmol/L was previously 
classified as prediabetic in ZDSD rats by Peterson, 2015 (115). Standard criteria in 
humans considers blood glucose > 11.0 mmol as diagnostic of diabetes and was used as 
a cut off in this study. 
27 
 
2.5 Kidney injury marker tests 
2.5.1 Kidney injury biomarker ELISA 
The Kidney Injury Panel 1 (rat) (Mesoscale, Rockville, USA) was used to measure KIM-1, 
NGAL, OPN and albumin in collected urine via electrochemiluminescence (ECL). The 
samples were diluted 1:5 with Diluent 29. The ELISA was done according the 
manufacturers instruction. After adding the read buffer, the plate was placed 
immediately into MESO QuickPlex SQ 120 and the measurement started. The data was 
visualized and analyzed using Discovery Workbench 4.0.  The hourly excretion rate of 
each biomarker was calculated as follows: 
????????????? ????????? ????????? ???? ????? [?? ??? ]
???? ?? ????????? ???? [?]
× ????? ????? ???????? [??] 
Values under detection limit were included as 0ng/h into the statistic. 
2.5.2 Urinary creatinine ELISA 
The QuantiChromTM Creatinine Assay Kit (DICT-500) (BioAssay systems, US) was used 
to measure creatinine in urine and blood samples. The samples were not diluted. A clear 
bottom 96-well plate was used for the assay. The optical density was read immediately 
after adding the working reagent and again after five min at 490 – 530 nm (peak 
510nm). For the quantification ClarioStar (BMG Labtech) was used. The detection limit 
was ???? ???????????.  
2.5.3 Creatinine clearance 
The creatinine clearance was calculated as following 
????? ?????? [??] × ?????????? ????????????? ?? ????? [?? ??? ]
?????????? ????????????? ?? ????? [?? ??? ] × ???? ?? ????????? ???? [???] 
Two samples were excluded for the calculation, because the plasma creatinine values 
were more increased than expected and blood contamination was suspected. 
2.6 Statistical analysis 
GraphPad Prism 6 and Excel were used for all statistical analysis. Data are described 
with mean and standard deviation (SD) or median and 25th to 75th quartiles, if not 
mentioned otherwise. The box plots show the median the 25th to 75th quartiles and the 
minimum and maximum values.  
Significance was shown in the graphs with * p < 0.05, ** p < 0.01 ***p < 0.001 and **** p 
< 0.0001 
At the age of 26 weeks the 44 ZDSD rats were divided into quartiles, according to their 
blood glucose. The animals from the upper glucose quartile (UGQ) were compared to the 
ones from the lowest glucose quartile (LGQ). Results were reported with median, 25th 
and 75th quartiles. The two groups were tested with a Mann-Whitney U test for 
differences in albuminuria, NGAL, OPN and KIM-1 secretion into urine, creatinine 
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clearance, food and water consumption and urine production. A p-value < 0.05 was 
considered significant. Only 11 out of total 22 LGQ and UGQ animals were used to 
measure the creatinine clearance, because most of the plasma samples were haemolytic 
and would have interfered with the creatinine result. Two values from the LGQ 
creatinine clearance were eventually excluded from the graph and statistic, because 
blood contamination was expected.  
To assess the correlation between urinary kidney injury biomarkers and blood glucose 
in ZDSD rats a Spearman’s rank correlation was performed. A p < 0.05 was significant. In 
addition the albumin excretion rate (AER) was correlated with NGAL, OPN and KIM-1 
excretion rate. 
Weekly measurements of weight and blood glucose are shown with mean and standard 
error mean (SEM). Blood glucose was not measured when the animals were 27- 30 
weeks old, because insulin treatment and surgery would have influenced the results. The 
mean weight and blood glucose, at 34 weeks of age, is calculate from only 6 rats in the 
BMT group and 8 rats in the RYGB(BMT) group. Differences in weight loss between 
intervention groups were assessed with an ANOVA, two tailed. 
Weight loss post surgery was shown with mean and SD. Weight gain of the rats in the 
RYGB and RYGB(BMT) was compared using a t-test, two tailed. A p-value < 0.05 was 
considered significant. 
The results from the 24 food intake are shown with median and 25th to 75th quartiles, 
since the data was not normally distributed. One ZDSD rat in the RYGB group was 
excluded from the graph and the statistics, because it did not eat during night. 
Hypersalivation with transient anorexia was expected. Including this rat, would have 
compromised the result. Because the data was not normally distributed, a Kruskal Wallis 
test, two sides, was performed to compare the median 24 h food intake of the sham, 
RYGB and RYGB(BMT) rats. A p-value of < 0.05 was considered significant.  
Blood glucose, and the kidney injury biomarkers were compared pre and 4 weeks post 
intervention, to assess the success of them. A Wilcoxon test was used to compare the 
two outcomes. Results with p < 0.05 were considered significant.  
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3 Results 
3.1 Subdivision of ZDSD rats into prediabetic and diabetic 
Forty-four ZDSD rats were categorized at the age of 25 weeks according to their blood 
glucose in normal blood glucose (< 7mmol/L), prediabetic (7 mmol/L – 11.0 mmol/L) 
and diabetic (> 11mmol/L). The blood glucose mean of the control (SD rats) at 26 weeks 
was 5.3 mmol/L. Fifty-two percent of the ZDSD rats were considered prediabetic and 
40.9% diabetic. Only 6.8% of ZDSD had normal blood glucose levels, see Figure 1. 
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Figure 1 ZDSD rats are predominately prediabetic by 26 weeks 
The graph shows the number of ZDSD rats being diabetic and prediabetic at 23 weeks and 26 
weeks compared to the SD rats. The total number of animals of ZDSD rats was n = 43 at 23 
weeks and n = 44 at 26 weeks. 
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3.2 Comparison between ZDSD rats having high and low blood glucose 
In order to state if high glucose has an impact on the body weight, 26 weeks old ZDSD 
rats were divided into quartile according to their blood glucose. The lower glucose 
quartile (LGQ) group was compared to the upper glucose quartile (UGQ) group. The 
median (25th – 75th quartile) blood glucose of the LGQ was 7.8 mmol/L (6.8 - 8.1) and 
from the UGQ 19.7 mmol/L (16.2 - 23.3). According to the blood glucose levels all rats 
from the UGQ were diabetic. The rats in the LGQ were either non diabetic or prediabetic. 
The rats from the UGQ group were on average heavier than the ones from the LGQ group 
with 557g (545 - 573) versus 541g (515 - 553). 
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Figure 2 Blood glucose and weight comparison between the lowest and highest quartiles 
A: Blood glucose levels were compared between ZDSD rats in the LGQ and the UGQ. B: Likewise 
the bodyweight was compared. Mann-Whitney U, two tailed, *** = p-value < 0.001 and * = p-
value < 0.05 
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3.2.1 Characteristics of the diabetic phenotype in ZDSD rats, when 26 weeks old 
The ZDSD from the UGQ and the LGQ were left in the metabolic cages over night for 17.5 
hours. The water and food intake and the urine production were compared. The rats 
from the UGQ showed polyuria, polydipsia and polyphagia, symptoms of diabetes, in 
accordance of their blood glucose. The rats from the UGQ produced significantly more 
urine than the rats from the LGQ, 34 ml (20-64) versus 11 ml (8 – 13, (p < 0.001). They 
ate 24.1 g (22.6 – 31.2) and 16.1 g (14.2 – 19.2) respectively and drank 52.7 g (39 – 64.0) 
versus 24.5 g (21.4 – 28.3) (both p < 0.0001), see Figure 3.  
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Figure 3 Urine production, food and water intake in the rats with high and low blood 
glucose. 
A: The graph shows the medians of the food intake, B: water consumption and C: urine 
production of the ZDSD rats in the UGQ versus the LGQ. **** = p-value < 0.0001 and *** = p-value 
< 0.001, Mann-Whitney U, two tailed.   
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3.2.2 ZDSD rats with high blood glucose excrete higher levels of kidney injury 
markers into the urine 
3.2.2.1 High blood glucose correlates positively with degree of albuminuria 
Correlation between afternoon blood glucose measurements of the ZDSD rat’s urinary 
albumin excretion rate at 23 and 26 weeks was investigated. At 23 weeks no correlation 
could be found between the two parameters, p > 0.05. At 26 weeks the plasma glucose 
level correlated positively with the urinary albumin excretion rate (r = 0.47, p = 0.0014). 
If the ZDSD rats from the UGQ and LGQ were compared, UGQ rats showed an increased 
albumin excretion rate with 156 μg/h (109 – 400) compared to 66.0 μg/h (58 -116) in 
the LGQ, p-value < 0.01). The median albumin excretion rate also differed between the 
control (SD rats) and the LGQ ZDSD rats, p < 0.001). 
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Figure 4 Correlation of blood glucose with urinary albumin excretion  
Graph A and B show the correlation of the urinary albumin excretion rate with the afternoon 
blood glucose in the ZDSD rats at 23 weeks, Spearman’s correlation Rank test, two tailed. Each 
dot represents an individual. Graph C shows the median of the albumin excretion rate in the 
control (SD rats) and the ZDSD rats from the UGQ and LGQ at 26 weeks. ** = p-value < 0.01, *** = 
p-value < 0.001, Mann-Whitney U test, two tailed, LGQ rats versus SD or versus UGQ rats. 
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3.2.2.2 Urinary NGAL excretion correlates with blood glucose in 26 week old 
ZDSD rats 
The afternoon blood glucose measurements of the ZDSD rats were correlated with their 
urinary NGAL excretion rate at 23 and 26 weeks. At 23 weeks no correlation could be 
found between the two parameters, p > 0.05. At 26 weeks the plasma glucose level 
correlated positively with the urinary NGAL excretion rate (r = 0.71, p < 0.0001). ZDSD 
rats with a high blood glucose at 26 weeks had an increased urinary NGAL excretion rate 
compared to the ones with lower blood glucose with 189 ng/h (154.5 – 296.8) versus 
92.9 ng/h (75.3 -118.4), p < 0.001. There was no difference in NGAL excretion rate 
between the control (SD rats) and the ZDSD rats with low blood glucose, p >0.05. 
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Figure 5 Correlation of blood glucose with urinary NGAL excretion 
Graph A and B show the correlation of the urinary NGAL excretion rate with the afternoon blood 
glucose in the ZDSD rats at 23 weeks, Spearman’s correlation Rank test, two tailed. Each dot 
represents an individual. Graph C shows the median of the NGAL excretion rate in the control 
(SD rats) and the ZDSD rats from the UGQ and LGQ at 26 weeks. *** = p-value < 0.001, Mann-
Whitney U test, two tailed, LGQ rats versus SD or versus UGQ rats. 
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3.2.2.3 Urinary OPN excretion correlates with blood glucose in 26 week old ZDSD 
rats 
The afternoon blood glucose measurements of the ZDSD rats were correlated with their 
urinary OPN excretion rate at 23 and 26 weeks. At 23 weeks no correlation could be 
found between the two parameters, p > 0.05. At 26 weeks the plasma glucose level 
correlated positively with the urinary OPN excretion rate (r = 0.64, p < 0.0001). ZDSD 
rats with a high blood glucose at 26 weeks had an increased urinary OPN excretion rate 
compared to the ones with lower blood glucose with 4.44 ng/h (3.06 -7.53) versus 1.83 
ng/h, p < 0.001. Further, the urinary OPN excretion was significantly increased in the 
ZDSD from the LGQ compared to the controls, p < 0.0001. 
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Figure 6 Correlation of plasma glucose with urinary OPN excretion 
Graph A and B show the correlation of the urinary OPN excretion rate with the afternoon blood 
glucose in the ZDSD rats at 23 weeks, Spearman’s correlation Rank test, two tailed. Each dot 
represents an individual. Graph C shows the median of the OPN excretion rate in the control (SD 
rats) and the ZDSD rats from the UGQ and LGQ at 26 weeks. *** = p-value < 0.001, **** = p-value 
< 0.0001, Mann-Whitney U test, two tailed, LGQ rats versus SD or versus UGQ rats. 
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3.2.2.4 Urinary KIM-1 excretion correlates with blood glucose in 26 week old 
ZDSD rats 
The afternoon blood glucose measurements of the ZDSD rats were correlated with their 
urinary KIM-1 excretion rate at 23 and 26 weeks. At 23 weeks no correlation could be 
found between the two parameters, p > 0.05. At 26 weeks the plasma glucose level 
correlated positively with the urinary KIM-1 excretion rate (r = 0.55, p < 0.001). ZDSD 
rats with a high blood glucose at 26 weeks had an increased urinary KIM-1 excretion 
rate compared to the ones with lower blood glucose with 0.76 ng/h (0.72 – 0.94) 
respectively 0.55 ng/h (0.49 – 0.63), p < 0.01. There was no difference in KIM-1 
excretion rate between the control (SD rats) and the ZDSD rats with low blood glucose, p 
>0.05. 
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Figure 7 Correlation of plasma glucose with urinary KIM-1 concentration 
Graph A and B show the correlation of the urinary KIM-1 excretion rate with the afternoon blood 
glucose in the ZDSD rats at 23 weeks, Spearman’s correlation Rank test, two tailed. Each dot 
represents an individual. Graph C shows the median of the KIM-1 excretion rate in the control 
(SD rats) and the ZDSD rats from the UGQ and LGQ at 26 weeks. ** = p-value < 0.01, Mann-
Whitney U test, two tailed, LGQ rats versus SD or versus UGQ rats. 
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3.2.2.5 Creatinine clearance does not differ in ZDSD rats with high and low blood 
glucose at 26 weeks 
The creatinine clearance did not differ in depending on the afternoon blood glucose in 
the ZDSD rats at 26 weeks, p-value = 0.1. 
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Figure 8 There was no difference in the creatinine clearance between the ZDSD rats in the 
upper and lower glucose quartile 
In graph A the median of the creatinine clearance of the UGQ and LGQ at 26 weeks was 
compared with a Mann-Whitney U test, two tailed. Graph B shows the creatinine clearance in 
relation to the afternoon blood glucose of each individual of the UGQ and LGQ group. 
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3.2.3 Urinary NGAL, OPN and KIM-1 excretion correlate with urinary albumin 
excretion rate 
A positive correlation was found between urinary albumin excretion rate and all the 
other tested kidney injury biomarkers in ZDSD rats at 26 weeks, p- value’s all < 0.05. The 
strongest correlation was found between albumin and OPN (r = 0.54, p < 0.001) and the 
weakest with KIM-1 (r = 0.37, p = 0.0139), Spearman’s rank correlation test. 
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Figure 9 Correlation of urinary albumin excretion rate and NGAL, OPN and KIM-1 
The graphs show the correlation between urinary albumin excretion and NGAL (A), OPN (B) and 
KIM-1 (C) in the 26 weeks old ZDSD rats, n = 44. Each dot represents an individual. 
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3.3 Haemorrhage is the main cause of death post RYGB surgery in ZDSD 
rats 
None of the rats having sham surgery died.   
The overall mortality from the RYGB surgery up to 10 days post surgery was 23%. Three 
animals died because of reactive haemorrhages < 24 h post surgery. One died within the 
first hour post surgery, the other two > 8 h - <24 h.  
Three more rats had to be humanly killed 2 days, 5 days and 6 days post surgery, 
because of chronic bleeding or peritonitis, due to leak of the jejunojejunal or the 
gastrojejunal anastomosis. The cause of death of the third rat was not further 
investigated 
A seventh rat was found dead 14 days post surgery. The cause of death was not further 
investigated. The animal had recovered well from surgery and had shown no adverse 
symptoms before death. 
Three weeks post surgery another ZDSD rat was euthanized because of excessive weight 
lost. A ZDSD rat from the BMT group died when 33 weeks old, from an oesophageal 
mass. The case was not further investigated 
Table 2 Cause of death post RYGB surgery 
Time post surgery Cause of death No. of animals 
< 1 h Intra operative bleeding 1 
< 24 h Reactive haemorrhage 2 
48 h Chronic haemorrhage 1 
 5 d Peritonitis 1 
> 5 d Unknown 2 
 
39 
 
3.4 Effect of medical treatment, weight loss and RYGB surgery on weight, 
blood glucose and kidney injury 
3.4.1 Most weight loss occurs in the RYGB(BMT) group 
All rats were weighed weekly. During the full study period, the SD rats gained more 
weight every week. The sham animals gained weight up to week 25. After sham surgery 
they lost up to 4.5% in one week, then no more surgery related weight loss was 
observed. When the sham animals grew older they, started to lose weight as their blood 
glucose increased, see Figure 10.  
The food restriction for the BMT animals was started at 29 weeks of age. Over two 
weeks they lost 5.5 – 10.2 % of their initial body weight. Liraglutide treatment was 
titrated towards 1mg/kg but discontinued temporarily at a dose of 0.5mg/kg due to 
anorexia. As a consequence they had lost up to 19.2 % of their initial body weight, when 
31 weeks old. To compensate the weight loss, the BMT rats were fed from then on 30g/d 
of standard chow to achieve the goal of 10% weight loss. With the weight gain, the blood 
glucose increased, see Figure 10. All ZDSD rats that had RYGB surgery lost initially 
weight. While the RYGB rats started to gain weight again 3 weeks post surgery, the rats 
also receiving medicaments continued losing weight, see Figure 10.   
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Figure 10 Development of the Body Weight and Blood Glucose from ZDSD and SD rats 
The arrows indicate the week of surgery. Blue: sham surgery for the Sham and BMT group. 
Green: RYGB surgery for RYGB(BMT) and Red: RYGB surgery for RYGB group.  
A: Body weight was measured weekly. Data are shown with mean and SEM bars.   
B: Blood glucose was measured in the afternoon. When the rats were 27 till 30 weeks old, no 
blood glucose was measured. Data are shown with mean and SEM bars. 
 
Most of the weight loss occurred in the first week post RYGB surgery as shown in Figure 
11. The RYGB and RYGB(BMT)  animals lost up to 20 % of their initial body weight in the 
first two weeks post surgery. However, three weeks post surgery the RYGB started to 
correct their body weight and gained some grams. The final weight loss of the BMT, 
RYGB and RYGB(BMT) was 89g ± 26.9, 78g ± 11.9 and 131g ± 17.2. Absolute numbers 
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correspond to -15.9% ± 1.8, -13.5% ± 6.3 and -23.0% ± 4.1 change in body weight post 
intervention for the BMT, RYGB and RYGB(BMT). The weight loss of all rats differed 
significantly between intervention groups, p < 0.0001, 1-way ANOVA, two tailed; only 
the weight of the RYGB and BMT group was the same. The main weight difference 
between RYGB and RYGB(BMT) formed 3-4 weeks post surgery, where it became 
significant, p < 0.01 t-test, two tailed. While the RYGB’s gained weight, the RYGB(BMT) 
continued losing weight. The RYGB(BMT) ate less than the RYGB, p = 0.0079, Mann-
Whitney U, two tailed, paired with the continuous weight loss, see Figure 11. The sham 
rat ate significantly more than the RYGB and the RYGB(BMT) with a median of 40g (27 – 
60) compared to 29g (26 – 30) and 23g (17 – 25), p = 0025, Kruskal-Wallis. However the 
sham lost up to 4.5% ± 2.5 of their body weight within four weeks, see Figure 11.  
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Figure 11 Body weight change 4 weeks post surgery and food intake 
Graph A shows the relative weight changes of the ZDSD 4 weeks after RYGB surgery or weight 
loss paired with medical treatment compared to the SD and sham animals. B) Percentage of 
weight loss one to four weeks post RYGB surgery. C) Food intake in 24 hours. ns = non 
significant ** = p < 0.01, *** p <0.001 
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3.4.2 RYGB(BMT) leads to the highest percentage of diabetes remission 
Before the intervention all rats were at least prediabetic. Three ZDSD’s in the sham 
group progressed from prediabetes to diabetes. Medical treatment and 15% weight loss 
(BMT) lead to an improvement of the hyperglycemia 4 weeks after treatment start. 
Diabetes remission to prediabetes was observed in all 3 previously diabetic rats. Fifty-
seven percent of the ZDSD rats were non diabetic four weeks post treatment. Blood 
glucose improved in 2 out of 4 diabetic ZDSD rats post –RYGB surgery. Twenty-two 
percent of the ZDSD rats had normal blood glucose four weeks post RYGB surgery. The 
combination of RYGB surgery and medical treatment showed a complete remission of 
diabetes in 89% of the rats. Only one animal was still prediabetic 4 week post 
intervention. Over all the blood glucose sank significantly in the BMT and RYGB(RYGB) 
group, but was not significantly changed in the RYGB group 4 weeks post surgery, p < 
0.05, Wilcoxon test, two tailed. In summary RYGB(BMT) showed the best results 
regarding hyperglycemia, followed by BMT and then RYGB, see Figure 12. 
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Figure 12 Number of rats having diabetes pre and post intervention 
Graph A shows the number of animals being prediabetic or diabetic before the intervention, 
while Graph B shows the distribution of the rats four weeks post intervention. 
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3.4.3 Urinary kidney injury markers post intervention 
3.4.3.1 BMT and a combination of RYGB and medical treatment improve 
albuminuria 
Albumin was already significantly increased in the urine of the ZDSD rats compared to 
SD’s, when 23 weeks old. This did not change when 26 weeks old as shown in 
Supplementary 3. Albuminuria worsened in the not treated sham group. When 33/34 
weeks old, four sham animals lost more than 1250 μg/h albumin into the urine, one 
animal even more than 12500μg/h. Albuminuria improved significantly in the ZDSD rats 
receiving medical treatment and food restriction (BMT) with a median AER of 103μg/h 
(73 – 144) before treatment and 50 μg/h (31 – 64) after treatment, p < 0.05, Wilcoxon 
test, two tailed. RYGB surgery alone did not improve significantly the AER. However, 
some individuals in the RYGB group show improvement. All ZDSD receiving a 
combination of RYGB surgery and medical treatment improved the AER 4 weeks post 
intervention with 156 μg/h (93 – 246) pre treatment versus 28 μg/h (20 – 58) post 
treatment, p < 0.05, Wilcoxon test, two tailed.  
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Figure 13 Urinary albumin excretion rate pre intervention (26 weeks old) and four weeks 
post intervention (33/34 weeks old) 
Two combined dots represent the urinary albumin excretion rate of an individual pre 
intervention and 4 weeks post intervention. Graph A shows the healthy control (SD rats), graph 
B the untreated ZDSD rats (SHAM) and graph C-E the different intervention grorups.  
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3.4.3.2 Urinary NGAL excretion reduced after RYGB surgery 
The NGAL concentration did not differ between the SD and ZDSD rats when 23 or 26 
weeks old as shown in Supplementary 3. A significant increase of the median NGAL 
excretion into the urine could be observed 4 weeks post intervention (33/34 weeks) 
compared to the baseline (26 weeks) in the sham 345ng/h (141 – 783) versus 122ng/h 
(94 – 140) , p < 0.05, the BMT 314ng/h (248 – 366) versus 50ng/h (31 – 64), p <0.05 
and the RYGB(BMT) group 442ng/h (300 – 804) versus 184 ng/h (94 – 180), p < 0.01, 
Wilcoxon test, two tailed. The NGAL excretion did not differ in the healthy control (SD 
rats) and the ZDSD rats receiving only RYGB surgery four weeks post-intervention.  
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Figure 14 Urinary NGAL excretion rate pre intervention (26 weeks old) and four weeks 
post intervention (33/34 weeks old) 
Two combined dots represent the urinary NGAL excretion rate of an individual pre intervention 
and 4 weeks post intervention. Graph A shows the healthy control (SD rats), graph B the 
untreated ZDSD rats (SHAM) and graph C-E the different intervention groups.  
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3.4.3.3 Urinary OPN excretion is reduced in the combination therapy of RYBG and 
medical treatment 
Urinary OPN excretion rate increased in the healthy controls from 26 weeks to 33 weeks 
from 0.48 ng/h (0.37 – 0.53) to 0.82 ng/h (0.51 – 1.21), (p < 0.05). Urinary OPN did not 
differ significantly in the sham and RYGB(RYGB) group pre and post intervention. The 
SD rats and the ZDSD rats in the BMT and RYGB group had higher urinary OPN excretion 
4 weeks post intervention, p < 0.05 Wilcoxon test, two tailed  
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Figure 15 Urinary OPN excretion rate pre intervention (26 weeks old) and four weeks 
post intervention (33/34 weeks old) 
Two combined dots represent the urinary OPN excretion rate of an individual pre intervention 
and 4 weeks post intervention. Graph A shows the healthy control (SD rats), graph B the 
untreated ZDSD rats (SHAM) and graph C-E the different intervention groups.  
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3.4.3.4 Urinary KIM-1 excretion is reduced when treated with a RYGB surgery, 
medical treatment or a combination of both 
Urinary KIM-1 excretion rate was stable in the healthy control group over the full study 
period. No significance change in the urinary KIM-1 excretion rate could be found pre 
and post intervention for the SD, sham, BMT, RYGB or the RYGB(BMT) group, p > 0.05, 
Wilxoxon test, two tailed. There was no difference of the median OPN excretion rate 
between all the groups 4 weeks post intervention, p > 0.05, Kruskal Wallis test, two 
tailed. However there was a trend of increased KIM-1 excretion in the sham group and 
some rats from the RYGB group in the 4 weeks follow up period. 
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Figure 16 Urinary KIM-1 excretion rate pre intervention (26 weeks old) and four weeks 
post intervention (33/34 weeks old 
Two combined dots represent the urinary KIM-1 excretion rate of an individual pre intervention 
and 4 weeks post intervention. Graph A shows the healthy control (SD rats), graph B the 
untreated ZDSD rats (SHAM) and graph C-E the different intervention groups. 
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3.4.3.5 Improvement of albumin excretion rate in medically managed diabetes 
leads to a increase of the NGAL excretion rate. 
All ZDSD rats in the BMT and RYGB (BMT) group showed an improvement of the AER 
four weeks after intervention start. However they all showed an increase in the urinary 
NGAL excretion at the same time, see Figure 17. 
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Figure 17 Albumin and NGAL excretion rate change 4 weeks post intervention 
Each dot represents an individual.  
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4 Discussion 
In this study different therapy forms to prevent diabetic kidney disease in T2DM were 
compared. ZDSD rats were used. They are a new rodent model for T2DM without a 
defect in the Leptin pathway. The healthy controls were the Sprague Dawleys (SD). 
During the study period significant variability in individual susceptibility regarding 
hyperglycemia, poyluria polydipsia, and kidney injury markers were observed within 
the ZDSD strain. These findings relative to findings in SD rats will be discussed in the 
first part of this chapter. The outcome of the interventions to prevent or delay diabetic 
kidney damage will subsequently be discussed. 
4.1 Characterization of the ZDSD rat  
In this study, a rat was considered diabetic, when their afternoon blood glucose was >11 
mmol/L. This value was two times higher than the blood glucose measured in the SD 
rats. A rat was hyperglycaemic when blood glucose > 7mmol/L, which was 30% higher 
than the blood glucose levels in the control. Not all ZDSD rats were diabetic, when they 
were divided into the different intervention groups (sham, BMT, RYGB, RYGB(BMT). 
Most of them were prediabetic (52%) as demonstrated in Figure 1. The number of 
diabetic rats was lower than expected. According to Peterson et. al. (2015) the average 
fed blood glucose should be > 17 mmol/L by 25 weeks, whilst in our study this was 12.5 
mmol/L. Interestingly, a weight gain stop was observed in the ZDSD rats of this study at 
the age of 20 – 22 weeks. This could have slowed down the development of 
hyperglycaemia and explain the difference in blood glucose between the two studies. 
The feed can be excluded as the cause. All rats from this and Petersons et al. (2015) were 
fed with Purina 5008, during the full study period. The weights were comparable and in 
both studies the rats were housed in pairs. The only difference was the time point when 
the blood was collected. Peterson et al. (2015) collected the blood early in the morning, 
while we collected it in the afternoon. However, at 24 week we collected blood in the 
morning and the obtained average blood glucose was significantly lower than the values 
at the age of 23 weeks. We observed a large variation in the blood glucose values. As a 
consequence, the ZDSD rats were divided into quartiles according to their blood glucose 
at 26 weeks. The animals in the upper glucose quartile were directly compared to those 
in the lower glucose quartile. Differences in weight, diabetic symptoms and kidney 
injury were investigated. The animals in the UGQ were all diabetic with a blood glucose 
of > 11 mmol/L. No animals in the LGQ were diabetic, but some were prediabetic. The 
ZDSD from the UGQ were heavier than those from the LGQ. This could be a possible 
explanation for the difference in blood glucose, Obesity is an important risk factor for 
diabetes (11). The weight difference possible evolved, because the rats in the UGQ ate 
more. Polyphagia is one on the main symptoms of diabetes mellitus. When diabetes 
mellitus progresses, not all the glucose is able to enter the cell, where it is metabolized to 
energy. The reason in T2DM is the increasing insulin resistance. As a consequence more 
food is needed to cover the energy waist.  
The rats in the UGQ showed polyuria and polydipsia, typical diabetes symptoms, which 
were not present in the LGQ individuals. Polyuria is caused through the loss of glucose 
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into the urine. The osmolarity of the primary urine increases and less fluid is reabsorbed 
(osmotic diuresis). As a consequence the urine becomes less concentrated and more 
fluid is lost. To compensate for the dehydration water intake elevates.   
Albumin, NGAL, OPN and KIM-1 were elevated in the urine of the UGQ rats compared to 
the LGQ ones. This findings are in accordance with a previous study, where diabetic 
ZDSD rats had increased kidney injury markers in the urine (72). The finding of polyuria 
and polydipsa in combination with increased kidney injury markers were expected. A 
recent study showed that already small changes in the albumin excretion rate within 
one year can worsen the prognosis to develop chronic kidney disease before the 
presence of microalbuminuria (116). NGAL and KIM-1 are associated with 
tubulointerstitial kidney damage. The NGAL excretion rate increases with the severity of 
the renal injury (117). As expected, our findings show that kidney damage is more 
advanced in the ZDSD rats with high blood glucose. We can agree with Peterson et al. 
(2017) that ZDSD rats are a suitable model to study DKD.  
Interestingly at 23 weeks albumin and OPN were elevated in the urine of ZDSD rats 
compared to the control rats (SD rats). This result differs from what was previously 
published. Peterson et al. (2017) found no difference in the albumin excretion between 
the SD and ZDSD rats before 26 weeks. Instead they measured an increased KIM-1 
excretion compared to the control already at 22 weeks. Recent studies have shown that 
human patients with only low levels of albumin excretions (< 30mg/24h) have an 
increased risk of hypertension and mortality (118). In fact, albuminuria seems to 
worsen in association with hypertension and metabolic changes (119). In healthy US 
veterans it has been demonstrated that the change in the amount of albumin excreted 
within one year, can be associated with the outcome of CKD. None of the tested 
individuals showed micro or macroalbuminuria at the beginning of their study (116). 
In our study we found a significant difference in the urinary OPN excretion between the 
SD and ZDSD rats, probably because of ongoing kidney damage in the ZDSD rats. Al-
Malki et al. (2014) found an association between albuminuria, podocyte damage and 
urinary OPN excretion(120). This suggests that the ZDSD rats suffer from podocyte loss 
and decreased glomerular function. However, Yamagucci et al. (2004) found that urinary 
OPN did not correlate well with the degree of kidney damage. He suggested that plasma 
OPN would be a better analyte.(121).  
Because of blood contamination and haemolysis only few samples could be analyzed for 
the creatinine clearance. No difference was found between the animals from UGQ and 
LGQ. Expected was a higher or normal creatinine clearance. It would be an 
approximation for the GFR. In early kidney damage the GFR is increased without 
albuminuria. Later the GFR goes back to a normal level, while microalbuminuria is 
present, before the GFR decreases more with the severity of the kidney damage. But 
recent studies have demonstrated that the GFR can be increased or already decreased 
before microalbuminuria is measured (5, 6).  
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4.2 Correlation of urinary kidney injury markers and glycaemia 
The urinary excretion rate of kidney injury markers (albumin, NGAL, OPN, KIM-1) was 
compared to the degree of hyperglycaemia. The goal was to asses if hyperglycaemia 
correlates with kidney injury. Our results showed that albumin, NGAL and OPN and KIM-
1 correlated with the degree of hyperglycaemia, when the animals were 26 weeks old. 
These findings suggest that massive hyperglycaemia causes more kidney damage than 
normal or only mild hyperglycaemia. Interestingly there was no correlation between any 
of the kidney injury markers and hyperglycemia, when the animals were  23 weeks of 
age. Suggesting that hyperglycemia has to be present for some time before kidney 
damage ensues. Huang et al. (2015) found an association between the albumin 
creatinine ratio (ACR) and fasting blood glucose. However, when the findings were 
adjusted to HbA1c the correlation was not anymore present (122). Increased HbA1c is 
the consequence of long term elevated blood glucose; supporting our theory that 
hyperglycaemia has to be present for a period before kidney damage occurs. It highlights 
the importance of treating at hyperglycaemia as early and adequately as possible to 
prevent progression to ESRD (31). 
The strongest correlation was found between urinary NGAL and glycaemia. Wang et al. 
(2006) published a correlation between glycaemia and serum NGAL (123). He even 
proposed NGAL as an independent risk factor for insulin resistance and hyperglycemia. 
However Elkhidir et al. (2017) could not find any correlation between serum NGAL and 
glycemic control (124). But in our study we showed, that there is a correlation with 
urinary NGAL and hyperglycaemia.  
The elevation of all four kidney injury parameters suggest that not only one part of the 
kidney is affected by hyperglycaemia, but the full kidney. Albuminuria is traditionally 
associated with endothelial dysfunction and increased intraglomerular pressure. NGAL 
is secreted mainly in the thick ascending limb of the Henle loop, distal tubulus, and the 
collecting duct, while KIM-1 is secreted in the proximal tubules in case of kidney injury 
(125). OPN is expressed by the distal tubular epithelial cells. In the case of kidney 
damage, it can also be up-regulated in the glomeruli  and by the macrophages found in 
the parenchyma (106, 107).  
In this study the excretion rate of NGAL, OPN and KIM-1 correlated with the AER. So far, 
albuminuria has been the gold standard to assess kidney damage. NGAL has been 
proposed as a marker for acute kidney injury, but can also be elevated in chronic kidney 
disease (81). With our results we can contribute that NGAL is a good marker for DKD. 
KIM-1 can be elevated in DKD and was previously proposed to be a possible marker for 
kidney injury (111). Supported by the findings of this thesis OPN can be a possible 
marker for DKD and kidney injury. However, to assess the real value of each of these 
markers in connection with the effective degree of kidney injury further studies are 
needed. 
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4.3 Mortality rate and complications 
The main cause of death during or < 48 h post surgery was bleeding. The mortality rate 
was 23% this was higher than expected. Most studies with RYGB surgeries report a 
maximum mortality of 20% (126). Only Inoue et al. (2007) published a higher mortality 
of 35% (127). A common reason for increased mortality is the surgeon. However in our 
case the surgery was performed by an experienced person. More likely an intrinsic 
susceptibility to bleeds in the ZDSD rat is the problem themselves. ZDSD rats become 
hypertensive by 9 weeks (128). During surgery, the used anaesthetic (isofluran) 
probably lowered the blood pressure. During recovery the blood pressure increased 
again. As a consequence a newly formed blood clot could have failed to seal the incision 
side and caused bleeding at the anastomosis. Unfortunately, blood pressure was not 
measured at any time during the study, to confirm this hypothesis. To prevent further 
bleeding, hypertension could be controlled with medical treatment before and shortly 
after surgery. An adjustment for the insulin therapy should be considered, because 
insulin can increases blood pressure shortly after initiation of the treatment. The blood 
pressure will normalize over time again. Because surgeries were done 1 week after 
initiation of insulin, the treatment could have contributed to the high number of reactive 
bleedings in this study (129). 
Many rats that had RYGB surgery showed transient anorexia with hypersalivation, till 
the end of the study. The cause could be a temporary obstruction in the oesophagus or at 
the gastrojejunal anastomosis, causing the animal to feel sick for a couple of hours. The 
hypersalivation passed, when animals were given soft food, to facilitate food passage.  
Metformin can cause GIT stress inducing nausea and diarrhoea (130). Diarrhoea could 
not be observed in our rats, but hypersalivation, a sign of stress, unease and nausea in 
rats. Maybe metformin contributed to the clinical signs, however, hypersalivation was 
also observed in the RYGB rats without medical treatment. 
4.4 Post surgery 
The main goal of the study was to see if kidney injury could be reduced with different 
forms of T2DM therapy and which one would be the most successful. Compared were 
rats having RYGB surgery, 15% weight loss in combination with medical treatment 
(metformin, ramipril, rosuvastatin and fenofibrate), or a combination of both. The 
outcomes were compared to the healthy controls (SD) and 9 ZDSD rats that received no 
treatment.  
4.4.1 Diabetes remission 
After RYGB surgery the rats lost up to 20 % of their initial body weight. But if they did 
not receive additional medical treatment post RYGB surgery, they regained weight till 
the end of the study. The same could be observed for the blood glucose. Hyperglycemia 
improved after RYGB surgery. But the overall success for diabetes remission was less 
than in the group that received additional medical treatment. In recent years it became 
clear, that RYGB surgery is not an absolute cure for T2DM. In a nationwide Swedish 
cohort study 67% of the patients that underwent RYGB surgery did not need further 
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medical treatment 2 years post surgery. But the number decreased to 61% seven years 
post RYGB surgery (131). In another study the initial T2DM remission was 68% within 5 
years post RYGB surgery, but 35% relapsed within the next 5 years(132). In that study 
poor preoperative glycemic control, insulin use and longer T2DM duration were 
considered risk factors for a relapse. Patients who gained more weight post RYGB 
surgery had a worse outcome for T2DM remission (132, 133). All this studies in 
combination with our findings suggest that RYGB surgery mainly reduces the amount of 
medication prescribed. But for a completely successful T2DM treatment medication can 
be still needed. 
The 15% weight loss and medical treatment group (BMT) had a better diabetes 
remission rate than RYGB surgery alone. Different studies have shown that weight loss 
can prolong the onset to diabetes in prediabetic patients, for example the Diabetes 
Prevention Program (DPP) in the US. In a 15 years follow up the cumulative incidence 
for the onset of diabetes from prediabetes could be reduced from 62 % in the placebo 
group to 55% in patients with 7% weight loss and 150 min moderate exercise per week 
and 56% when treated only with metformin(134). In the Let’s Prevent study in the UK 
took a more pragmatic approach to prevent diabetes. Their goal was to bring the 
lifestyle intervention into primary care, in a more realistic and cost effective way. They 
used a risk score in combination with a blood test to determine people at risk. Then they 
invited the patients to a 6 hour group education session, which were combined with a 3 
hour refresher session one and two years after the beginning of the program in 
combination with a short phone call every three months. The goal was to motivate the 
people to lose at least 5% of their body weight, reduce fat intake, increase the 
percentage of monosaturated fats and the fibre intake and encourage moderate exercise 
(135). In the 3 years follow up a non significant 26% reduction in onset to diabetes 
could be observed. Smokers and people with lower income were more likely to fail 
(136). But weight loss is not only beneficial in patients with prediabetes, but also in 
patients with T2DM. The Action for Health in Diabetes (AHEAD) study found a positive 
association between 5-10% weight loss with improvement of glycaemia, blood pressure, 
triglycerides and HDL-cholesterol in T2DM patients in a 1 year follow up. The results 
were even better when the weight loss was 10-15 % of the initial body weight (137). 
The ongoing Diabetes Remission Clinical Trial (DiRECT) wants to test T2DM remission 
in general practice through a special diet that should help the participants to lose > 15 
kg of their initial body weight (138). The first results from that study show that 24 % of 
the participants in the weight loss group could achieve the weight loss goal. T2DM 
remission was achieved in 86 % of the participant that lost > 15 kg and 46 % when 10-
15 kg weight loss. Less anti-diabetic antihypertensive drugs were prescribed in the 
intervention group (139). 
In our study the ZDSD rats with RYGB surgery in combination with medical treatment 
(RYGB(BMT) had the highest diabetes remission rate. Only one individual was still 
diabetic 4 weeks post surgery. To control the hyperglycemia after surgery the rats 
received initially only metformin. Later fenofibrate and ramipril was added. The weight 
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loosing properties of the RYGB surgery in combination with the weigh reducing effects 
of the used medication, was probably the main cause of the successful diabetes 
remission in the RYGB(BMT). Striking was the ongoing weight loss in the RYGB(BMT) 
group A possible explanation for the ongoing weight loss was the reduced food intake, 
see Figure 11 Body weight change 4 weeks post surgery and food intake previous study 
showed that RYGB surgery reduces food intake and enhances weight loss, mainly in the 
first month post surgery (140). The same could be observed in this study. The main 
weight loss occurred in the first 10 days post surgery. In addition metformin 
hydrochloride has been shown to, not only improve hyperglycemia, but also support 
weight loss (134). One of the main mechanism is a reduction in food intake (141). It can 
block glucose absorption directly in the intestine (142), it improves leptin and insulin 
sensitivity (143, 144) and it reduces hepatic gluconeogenesis (145). In addition, 
different studies have demonstrated that fibrates can inhibit the effect of weight gaining 
medicaments and even induce mild weight loss on their own (146, 147). For future 
studies, it would be interesting to know if RYGB in combination with only metformin 
would be enough to achieve a high diabetes remission rate. 
The fact that the sham rats also lost weight, when showing severe T2DM symptoms, 
demonstrates that mild weight loss is not enough for diabetes remission. Or maybe 
remission can be achieved only at an early stage of diabetes. This would not be 
surprising. When T2DM progresses more and more beta cells are destroyed. Insulin 
production will be permanently reduced. The weight loss is then a consequence of 
energy waist, because the glucose cannot be used effectively. 
4.4.2 Kidney injury 
Not only hyperglycemia and obesity improved in the RYGB(BMT) group, but also the 
albumin excretion rate. The same could be observed in the BMT group. The effect was 
less prominent in the RYGB group. Sumida et al. (2017) showed that already a minor 
increase in the urinary albumin excretion rate over one year, has negative effects on the 
outcome of the kidney disease(116). Reid et al. (2014) showed that albuminuria 
improved after RYGB surgery and regression from micro- to normoalbuminura was 
observed in > 80% of the patients (148). Two studies compared RYGB to intensive 
medical treatment. In both studies the albumin creatinine ratio improved only in the 
RYGB group (149, 150). However, also most of the RYGB patients received medical 
treatment in addition to the surgery, so they would correspond to the RYGB(BMT) 
groups in this study. Indeed, the RYGB(BMT) rats showed an significant improvement of 
albuminuria 4 weeks post surgery. The improvement was not significant when only 
RYGB surgery was performed. The results of this study suggest, that the medical 
supporting treatment is necessary, to improve albuminuria and hyperglycemia.  
The BMT group had significant improvements of albuminuria. Ramipril is very effective 
in reducing albuminuria in patients with T2DM(151). Rosuvastatin can enhance the 
positive effect of the ACE inhibitors. It reduces the oxidative stress, caused by 
hyperglycaemia, on the kidney cells. As a consequence cell damage and cell loss is 
reduced and less protein lost (40).  
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In a recent study a diabetic rat model (db/db) was treated with fenofibrate. An in 
improvement of albuminuria and morphological kidney changes was reported (42). 
Other than the RYGB(BMT) group, the BMT’s also received liraglutide, a GLP-1 agonist. 
Studies have demonstrated the positive effect of Liraglutide when added to the diabetic 
treatment. Albuminuria could be reduced and progression of CKD in case of DKD was 
slowed down (152, 153).   
A special focus should be put on the weight loss in the BMT group. Afshinnia et al. 
(2010) showed in a meta analysis, that each 1kg weight loss reduces urinary albumin 
excretion about 1.1 mg/24h. In conclusion, our results suggest that that RYGB surgery 
has better outcomes regarding albuminuria when combined with medical treatment. 
Good medical treatment paired with 15% weight loss, has as good outcomes as 
RYGB(BMT).  
In this study none of the intervention reduced the NGAL excretion into the urine. The 
RYGB group showed no improvement, but also no increase in the NGAL secretion 4 
weeks post surgery. The similar result was published in a study, where 22 severely 
obese adolescent without microalbuminuria showed that urinary NGAL was not reduced 
one year after RYGB surgery (114). However these results are not completely 
comparable, since our rats were diabetic, and adults. 
While a significant improvement in albuminuria in the BMT and RYGB(BMT) group was 
observed, NGAL excretion significantly worsened in the same groups. Some NGAL can be 
pre-renal in origin as it is small enough to be filtered. Filtered NGAL is normally 
reclaimed by the same pathway as used for albumin in the proximal tubule. However the 
correction of albumin, but sustained NGAL excretion, is indicative of ongoing renal 
injury in the nephron downstream of the proximal tubule. Many of the medicaments 
used in this study can have negative effects on the kidney. Fenofibrate or rosuvastation 
and ACE inhibitors can cause acute kidney injury, if overdosed(154), resulting in an 
elevation of NGAL (155, 156). In this study none of the rats received an individual 
medical treatment plan. A slight overdosing in some of the animals could be possible. 
However most likely the elevated urinary NGAL were not high enough to speak of an AKI 
in the RYGB(BMT) or BMT animals. To evaluate which drug is responsible for these 
changes, further studies have to be made. Urinary NGAL concentrations have been 
associated with progression of chronic kidney disease (81). Compared to KIM-1, NGAL 
levels in the urine can be associated with the severity of albuminuria (157).  
Urinary KIM-1 excretion rate was low in all groups before the intervention. However, its 
urinary excretion rate increased, when the animals did not receive any treatment, but 
was not significant. It did not change in the BMT, RYGB and RYGB(BMT) group. Like 
NGAL, KIM-1 is a marker for proximal tubulus damage. High urinary KIM-1 excretion has 
been associated with a faster progression of DKD, because of a faster decrease of the 
kidney function (GFR) (82). Increased urinary KIM-1 and NGAL excretion in 
combination with microalbuminuria enhances the risk for ESRD and death further 
(158). Carvahlo et al. (2016) showed that an increase of urinary NGAL or KIM-1 can 
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occur before the onset of microalbuminuria (159). This was not the case in our study. 
But we used a rat model instead of humans. 
Most studies focus on serum OPN rather than urinary OPN, after Yamagucci et al. (2004) 
showed that only plasma OPN correlated with the progression of DKD to ESRD. The 
study involved 229 patients with T2DM (121). Another preliminary study showed that a 
lower serum OPN is associated with increased insulin sensitivity, and more body weight 
loss after RYGB surgery and a overall improvement of the outcome (160). However, in 
our study we found a positive correlation between albuminuria and urinary OPN 
excretion rate and a correlation between urinary OPN and the degree of hyperglycaemia. 
Interestingly, the interventions like RYGB surgery or medical treatment did not decrease 
the OPN excretion rate. Instead a increase in the urinary OPN was observed in the BMT 
RYGB and SD group. Plus there was a non significant trend for elevated urinary OPN in 
the sham group. The elevation in the SD and sham group could be explained with an 
increase in bodyweight an obesity (11). The increase in the BMT group was surprising. A 
reduction of urinary OPN was expected, because ramipril has been shown to reduce the 
gene expression of OPN in the kidney. However, if ACE inhibitors can prevent 
tubulointerstitial fibrosis stays controversial (161, 162).  
In summary, not all animal could be treated successfully with RYGB surgery alone If 
medical treatment was added to the surgery, the best outcomes could be observed. 
Interestingly 15% weight loss in combination with oral medical treatment was almost as 
successful in improving hyperglycaemia as the RYGB(BMT) combination. The most 
surprising finding was, that with the improvement of albuminuria in the RYGB(BMT) 
and BMT group NGAL excretion rate increased. Overdosing of the medication, could be a 
possible explanation for these findings. To prove this, further experiments with 
individual treatment plans or different drug combinations are needed. Further, in this 
study the term kidney damage is used, referring to elevated kidney injury markers. To 
evaluate the effective kidney damage, histology will be needed.  
4.4.3 Limitations 
Tight management of weight loss was challenging and may have influenced the results.
  
As medication was given with the food, precise dosing may not have occurred 
The medication was not adjusted for every individual, as it would be in humans. Some 
rats might have received medical treatment that was not necessary.  
In general, this study should be completed with the histological findings of the kidneys.  
4.4.4 Conclusion 
Only about 50% of the ZDSD rats were diabetic at the age of 26 weeks. This was a lower 
number than expected. ZDSD rats within the lowest blood glucose quartile had less 
kidney injury and showed no diabetic symptoms compared to the rats within the upper 
glucose quartile, when 26 weeks old. A significant difference could be observed 
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regarding, polyuria, polydipsia, polyphagia and the amount of excreted kidney injury 
markers into the urine between the rats from the upper and lower glucose quartile. 
Different to other studies, we found a correlation between hyperglycaemia and the 
urinary excretion rate of all testes kidney injury markers (albumin, NGAL, OPN, KIM-1) 
at the age of 26 weeks. There was no correlation present when the animals were 
younger, and no correlation was assessed at a later time point. The most interesting 
finding was the correlation of hyperglycaemia with urinary OPN.  
The ZDSD rats that underwent RYGB surgery did not show any significant improvement 
regarding hyperglycaemia or the concentration of kidney injury markers in the urine. 
Combination of surgery with medical treatment had better outcome. Hyperglycaemia 
was controlled better and albuminuria reduced more effectively. No change in the KIM-1 
excretion could be observed. Interestingly, an elevated NGAL excretion could be 
observed in the RYGB(BMT) and in the BMT group 4 weeks after start of the 
intervention, surprising when contrasted with effect on urinary albumin excretion and 
suggestive of  ongoing kidney injury.  
In conclusion this study has deepened insights into the diabetic phenotype in ZDSD rats 
and the associated degree of DKD. The relative impact of intensive interventions of 
weight, metabolic control and urinary surrogates of renal injury has provided some 
thought-provoking data suggesting that remission of albuminuria may not be entirely 
indicative of reduced renal injury. 
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6 Appendix 
6.1 Insulin optimisation protocol 
The Glucose target from the morning glucose was 6 - 9mmol/L. Over seven days, glucose 
was measured daily in the morning and then insulin degludec (Tresiba®, Novo Nordisk 
A/S) was injected sc. 
The starting dose of insulin was defined as following: 
 
Table 3 Insulin starting dose 
Insulin starting dose 
Blood glucose level in the 
morning Insulin (Units) 
< 9 0 
9 - 13 4 
13 -17 6 
17 - 21 8 
21 - 25 10 
> 25 12 
 
The insulin dose was adjusted every two to three days following the protocol in Table 4., 
Because many ZDSD responded to a new insulin dose after 3 days and not two. The 
maximum dose of 20 units per rat was not exceeded, to reduce the risk of 
hypoglycaemia.  
Table 4Insulin adjustments 
Insulin dose adjustments 
Blood glucose level in the 
morning 
Insulin (Units) 
< 6 -4 
6 – 9 0 
9 – 13 +4 
13 – 17 +6 
17 – 21 +8 
21 - 25 +10 
> 25 +12 
 
The day before surgery only half the units from the day before were given. 
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6.2 Liraglutide Titration Protocol 
Liraglutide was started at the age of 30 weeks in the BMT group. The dose was adjusted 
every day according to Table 5. Water consumption was monitored, to prevent 
hypodipsia and dehydration. The ZDSD rats became anorexic, when administrated 
0.5mg/kg of Liraglutide. The dose was kept on 0.5mg/kg for another day then the 
treatment was stopped, because of the animal welfare. Liraglutide was reintroduced 
when the ZDSD rats were back to 10% weight loss on a constant rate of 0.2 mg/kg, till 
the end of the study. 
Table 5 Liraglutide titration adjustments 
Liraglutide Titration 
Day Liraglutide [mg/kg] 
1 0.025 
2 0.025 
3 0.05 
4 0.1 
5 0.15 
6 0.2 
7 0.3 
8 0.4 
9 0.5 
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6.3 Rat scoring system 
For pain evaluation of the animals during the study the rat grimace scale was used, that 
was developed by Sotocinal et al. (2011) (163). If the pain score was more than 3, a 
0.05mg/kg Buprenorphin subcutaneous injection was given. In addition skin lesions, 
wounds and discharge were reported. To evaluate further actions and possible 
endpoints during the study, Table 6 was used.  
Table 6 
Feature Score Description 
Appearance 
0 Normal 
1 
General lack of grooming/mild 
dehydration 
2 Dehydration/hunched 
3 Severe dehydration 
Weight 
0 weight loss less than 5% 
1 Body weight < 10% decrease 
2 Bodyweight < 10-20% decrease 
3 Bodyweight < 30% decrease 
Behaviour 
0 Normal 
1 Minor depression or exaggerated response 
2 Decreased mobility or alertness/isolation 
3 Vocalisation/restless or still/precomatose 
Respiratory 
0 normal 
1 slight changes/increased rate only 
2 Increased rate with abdominal breathing 
3 Decreased rate with abdominal breathing 
Actions:  Score 0 Normal – no action  
 Score 1-4 Observation, consider action  
 Score 5-7 Suffering administration analgesia/fluids
   
 Euthanasie if a) Score of 3 in any single category, except 
 weigth* b) total score of 7 or above, c) other indications 
* A 30% weight loss in the rats with RYGB surgery is expected. If the rat only scored 3 in 
weight, but looks healthy, the necessity of euthanasia can be discussed 
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6.4 Parameters of the study groups before intervention 
The afternoon blood glucose was the same in Sham 9.5 mmol/L (8.1 – 12.3), BMT 9.8 
mmol/L (8.2 – 12.7), RYGB 10.9 mmol/L (10.4 – 14.0) and RYGB(BMT) 10.9 mmol/L 
(9.1 – 18.9). The median blood glucose of the SD was 5.3 mmol/L (5.2 – 5.5). The weight 
was the same in Sham 520g (517 – 556), BMT 548g (517 – 559), RYGB 558g (549- 567) 
and RYGB(BMT) 550g (531 – 570), Kruskal-Wallis two tailed. The weight of the SD was 
549g (511 – 565). There was no difference in albumin loss into the urine for sham 109 
μg/h (60 - 323), BMT 103 μg/h (73 – 144), RYGB 190 μg/h (116 – 268) RYGB(BMT) 156 
μg/h (93 - 247), Kruskal-Wallis, two tailed. The AER of the SD was 28 μg/h (28 - 13). 
There was no difference in the NGAL concentration in the urine for sham 122 ng/h (100 
- 191), BMT 119 ng/h (93- 143), RYGB 133 ng/h (124 - 188), RYGB(BMT) 118 ng/h (94 - 
180), Kruskal-Wallis two tailed. The NGAL excretion of the of the SD was 77 ng/h (60 - 
133). There was no difference in the OPN concentration in the urine for sham 2.57 ng/h 
(1.41 – 4.86), BMT 1.50 ng/h (1.34 – 1.72), RYGB 2.70 ng/h (2.45 – 4.42), RYGB(BMT) 
3.03 ng/h (1.28 – 4.71), Kruskal-Wallis two tailed. The OPN excretion rate of the SD was 
0.48 ng/h (0.37 – 0.53).   
There was no difference in the KIM-1 concentration in the urine for sham 0.605 ng/h 
(0.528 – 0.730), BMT 0.641 ng/h (0.468 – 0.829), RYGB 0.630 ng/h (0.577 – 0.746), 
RYGB(BMT) 0.622 ng/h (0.494 – 0.743), Kruskal-Wallis two tailed. The KIM-1 excretion 
rate of the SD was 0.515 ng/h (0.289 – 0.683). 
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Supplementary 1 Parameters of the different groups before intervention 
Graph A-F show the median and 25th – 75th quartile, inclusive minimum and maximum values of 
the afternoon blood glucose, weight, albumin, NGAL, OPN, and Kim-1 excretion rate of each 
study group at 26 weeks. each dot represents an individual. 
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6.5 Glucose values of the intervention groups four weeks post intervention 
The median of the blood glucose did not differ between the sham, BMT RYGB and RYGB 
(BMT) 4 weeks post surgery 33.3 mmol/L (10.9 – 33.3), 6.9 mmol/L (6.3 – 11.2), 8.9 
mmol/L (7.0 – 15.7), 5.8 mmol/L (5.2 – 6.1), Kruskal-wallis, two tailed. The medium of 
the SD was 5.7 mmol/L (5.1- 6.2).  
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Supplementary 2 Afternoon blood glucose four weeks post intervention 
The graph shows the median and 25th – 75th quartile, inclusive minimum and maximum values of 
the afternoon blood glucose. Each dot represents an individuum. 
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6.6 Comparison of the urinary kidney injury markers of ZDSD and SD rats 
at the age of 23 and 26 weeks  
When 23 weeks old the ZDSD rats lost significantly more albumin into the urine 
compared to the SD rats (control) with a median of 116 μg/h (60 -173) compared to 22 
μg/h (19 – 40), p < 0.0001, Mann Whitney U, two tailed. This did not change when they 
were 26 weeks old. The ZDSD had an albumin excretion rate of 137 μg/h (78 – 246) 
compared to 28 μg/h (15 – 36), p < 0.0001 , Mann-Whitney U, two tailed. The NGAL 
excretion rate into the urine was 102 ng/h (78 – 120) for ZDSD and 105 ng/h (79 – 147) 
for the control, at 23 weeks and 126 ng/h (94 – 158) respectively 77 ng/h (60 – 113) at 
26 weeks. At both time points there was no difference between the SD and the ZDSD 
rats. The 23 weeks old ZDSD rats showed already an elevated OPN excretion with 1.51 
ng/h (1.06 – 2.77) compared to the control (SD rats) 0.68 ng/h (0.51 – 0.85), p = 0.0007, 
Mann-Whitney U, two tailed. The same was observed when 26 weeks old. ZDSD excreted 
2.24 ng/h (1.50 – 4.17) and the SD 0.48 ng/h (0.37 – 0.53), p <0.0001, Mann-Whitney U, 
two tailed. The KIM-1 excretion rate into the urine was 0.630  ng/h (0.505 – 0.758) for 
ZDSD and 0.370 ng/h (0.350 – 0.590) the control, at 23 weeks and 0.630 ng/h (0.543 – 
0.730) respectively 0.520 ng/h (0.290 – 0.680) at 26 weeks. At both time points there 
was no difference between the SD and the ZDSD rats. 
 
a
lb
u
m
in
 e
x
c
r
e
ti
o
n
 r
a
te
[μ
g
/
h
]
2 3  w e e k s 2 6  w e e k s
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
6 0 0
7 0 0
8 0 0
Z D S D  [ n  =  4 4 ] S D  [ n  =  7 ]
* * * * * * * *
2 3  w e e k s 2 6  w e e k s
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
6 0 0
Z D S D  [ n  =  4 4 ] S D  [ n  =  7 ]
N
G
A
L
 e
x
c
r
e
ti
o
n
 r
a
te
[n
g
/
h
]
O
P
N
 e
x
c
r
e
ti
o
n
 r
a
te
[n
g
/
h
]
2 3  w e e k s 2 6  w e e k s
0
2
4
6
8
1 0
1 2
1 4
1 6
Z D S D  [ n  =  4 4 ] S D  [ n  =  7 ]
* * *
* * * *
K
IM
-1
 e
x
c
r
e
ti
o
n
 r
a
te
[n
g
/
h
]
2 3  w e e k s 2 6  w e e k s
0 . 0
0 . 5
1 . 0
1 . 5
2 . 0
2 . 5
Z D S D  [ n  =  4 4 ] S D  [ n  =  7 ]
A B
C D
 
Supplementary 3 Kidney injury markers excretion into urine at the age of 23 and 26 
weeks 
The graphs show the median and 25th – 75th quartile, inclusive minimum and maximum values of 
the albumin excreation rate (A), NGAL (B), OPN (C) and KIM-1 excretion rate. *** = p-value < 
0.001, **** = p-value < 0.0001, Mann-Whitney U test, two tailed.
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